Peroxisome proliferator-activated receptor gamma
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein homooligomer Homooligomer Protein × 2 PDB declaration: dimeric（2） Consistent with protein copy count | Chain A； UniProt 223–504 Chain B； UniProt 223–504 | Fragment：ligand binding domain, UNP residues 223-504 | JJB N-(benzylsulfonyl)-4-propoxy-3-({[4-(pyrimidin-2-yl)benzoyl]amino}methyl)benzamide × 1 | X-RAY DIFFRACTION X-ray crystallization conditions：VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES | Resolution 2.20 Å R-free 0.256 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 4YT1 | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1FM6 THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES. Deposited 2000-08-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain D
204–475（272 aa）
Fragment：LIGAND BINDING DOMAIN - RESIDUES 206 - 477
|
Not recorded | 9CR (9cis)-retinoic acid × 1 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；17% PEG 4K, 200mM NaSCN, 8% Ethylene Glycol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.10 Å R-free 0.292 |
| 1FM6 THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND ROSIGLITAZONE AND CO-ACTIVATOR PEPTIDES. Deposited 2000-08-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain X
204–475（272 aa）
Fragment：LIGAND BINDING DOMAIN - RESIDUES 206 - 477
|
Not recorded | 9CR (9cis)-retinoic acid × 1 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；17% PEG 4K, 200mM NaSCN, 8% Ethylene Glycol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.10 Å R-free 0.292 |
| 1FM9 THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMMA LIGAND BINDING DOMAINS RESPECTIVELY BOUND WITH 9-CIS RETINOIC ACID AND GI262570 AND CO-ACTIVATOR PEPTIDES. Deposited 2000-08-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain D
234–505（272 aa）
Fragment：LIGAND BINDING DOMAIN - RESIDUES 206 - 477
|
Not recorded | 9CR (9cis)-retinoic acid × 1 570 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；17% PEG 4K, 200mM NaSCN, 8% Ethylene Glycol , pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 22K
|
Resolution 2.10 Å R-free 0.268 |
| 1I7I CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST AZ 242 Deposited 2001-03-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
225–505（281 aa）
Fragment：LIGAND BINDING DOMAIN
|
Not recorded | AZ2 (2S)-2-ETHOXY-3-[4-(2-{4-[(METHYLSULFONYL)OXY]PHENYL}ETHOXY)PHENYL]PROPANOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；sodium citrate, hepes, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.35 Å R-free 0.284 |
| 1I7I CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST AZ 242 Deposited 2001-03-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
225–505（281 aa）
Fragment：LIGAND BINDING DOMAIN
|
Not recorded | AZ2 (2S)-2-ETHOXY-3-[4-(2-{4-[(METHYLSULFONYL)OXY]PHENYL}ETHOXY)PHENYL]PROPANOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；sodium citrate, hepes, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.35 Å R-free 0.284 |
| 1K74 The 2.3 Angstrom resolution crystal structure of the heterodimer of the human PPARgamma and RXRalpha ligand binding domains respectively bound with GW409544 and 9-cis retinoic acid and co-activator peptides. Deposited 2001-10-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain D
234–505（272 aa）
Fragment：ligand binding domain residues - 206 - 477
|
Not recorded | 9CR (9cis)-retinoic acid × 1 544 2-(1-METHYL-3-OXO-3-PHENYL-PROPYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；295 K；PEG4K, NaSCN, Ethylene Glycol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.30 Å R-free 0.279 |
| 1KNU LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA IN COMPLEX WITH A SYNTHETIC AGONIST Deposited 2001-12-19 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
232–505（274 aa）
Fragment：LIGAND BINDING DOMAIN
Chain B
232–505（274 aa）
Fragment：LIGAND BINDING DOMAIN
|
Not recorded | YPA (S)-3-(4-(2-CARBAZOL-9-YL-ETHOXY)-PHENYL)-2-ETHOXY-PROPIONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；294 K；CITRIC ACID, TRIS-HCL, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 294.0K
|
Resolution 2.50 Å R-free 0.264 |
| 1NYX Ligand binding domain of the human peroxisome proliferator activated receptor gamma in complex with an agonist Deposited 2003-02-14 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
230–505（276 aa）
Fragment：Ligand binding domain
Chain B
230–505（276 aa）
Fragment：Ligand binding domain
|
Not recorded | DRF (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；Citrate, Tris, pH 8, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.65 Å R-free 0.306 |
| 1PRG LIGAND BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA Deposited 1998-07-02 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
205–474（270 aa）
Fragment：LBD (LIGAND BINDING DOMAIN), RESIDUES 207-476
Chain B
205–474（270 aa）
Fragment：LBD (LIGAND BINDING DOMAIN), RESIDUES 207-476
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；VAPOR DIFFUSION METHOD, HANGING DROP TECHNIQUE, 1.4M SODIUM CITRATE, 100MM HEPES, PH 7.5
|
Resolution 2.20 Å R-free 0.318 |
| 1RDT Crystal Structure of a new rexinoid bound to the RXRalpha ligand binding doamin in the RXRalpha/PPARgamma heterodimer Deposited 2003-11-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain D
235–505（271 aa）
Fragment：ligand binding doamin
|
Not recorded | L79 (S)-(2E)-3[4-(5,5,8,8-TETRAMETHYL-5,6,7,8-TETRAHYDRO-2-NAPHTHALENYL)TETRAHYDRO-1-BENZOFURAN-2-YL]-2-PROPENOIC ACID × 1 570 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；295 K；17% PEG 4K, 200mM NaSCN, 8% ethylene glycol, 8% glycerol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K, pH 7.50
|
Resolution 2.40 Å R-free 0.259 |
| 1ZEO Crystal Structure of Human PPAR-gamma Ligand Binding Domain Complexed with an Alpha-Aryloxyphenylacetic Acid Agonist Deposited 2005-04-19 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Fragment：Ligand Binding Domain (LBD), residues 203-477
Chain B
231–505（275 aa）
Fragment：Ligand Binding Domain (LBD), residues 203-477
|
Not recorded | C01 (2S)-(4-ISOPROPYLPHENYL)[(2-METHYL-3-OXO-5,7-DIPROPYL-2,3-DIHYDRO-1,2-BENZISOXAZOL-6-YL)OXY]ACETATE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；0.95 M Trisodium Citrate, 0.1 M Tris/HCl, 1 mM TCEP, pH 8.5, temperature 298K, VAPOR DIFFUSION, SITTING DROP
|
Resolution 2.50 Å R-free 0.280 |
| 1ZGY Structural and Biochemical Basis for Selective Repression of the Orphan Nuclear Receptor LRH-1 by SHP Deposited 2005-04-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Fragment：PPARgamma Ligand Binding Domain
|
Not recorded | BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；PEG 3350, tri-sodium citrate, ethylene glycol, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.80 Å R-free 0.258 |
| 2ATH Crystal structure of the ligand binding domain of human PPAR-gamma im complex with an agonist Deposited 2005-08-25 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：ligand binding domain
Chain B
235–505（271 aa）
Fragment：ligand binding domain
|
Not recorded | 3EA 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；20% PEG3350, 0.2 Sodium Citrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.28 Å R-free 0.288 |
| 2F4B Crystal structure of the ligand binding domain of human PPAR-gamma in complex with an agonist Deposited 2005-11-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN
|
Not recorded | EHA (5-{3-[(6-BENZOYL-1-PROPYL-2-NAPHTHYL)OXY]PROPOXY}-1H-INDOL-1-YL)ACETIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；20% PEG3350, 0.2 Sodium Citrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.07 Å R-free 0.288 |
| 2F4B Crystal structure of the ligand binding domain of human PPAR-gamma in complex with an agonist Deposited 2005-11-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；20% PEG3350, 0.2 Sodium Citrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.07 Å R-free 0.288 |
| 2FVJ A novel anti-adipogenic partial agonist of peroxisome proliferator-activated receptor-gamma (PPARG) recruits pparg-coactivator-1 alpha (PGC1A) but potentiates insulin signaling in vitro Deposited 2006-01-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 207-477
|
Not recorded | RO0 1-(3,4-DIMETHOXYBENZYL)-6,7-DIMETHOXY-4-{[4-(2-METHOXYPHENYL)PIPERIDIN-1-YL]METHYL}ISOQUINOLINE × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；20% PEG3350, 0.2M magnesium chloride, 0.1M Tris, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.99 Å R-free 0.246 |
| 2G0G Structure-based drug design of a novel family of PPAR partial agonists: virtual screening, x-ray crystallography and in vitro/in vivo biological activities Deposited 2006-02-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：Ligand binding domain(residues 207-477)
Chain B
235–505（271 aa）
Fragment：Ligand binding domain(residues 207-477)
|
Not recorded | SP0 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；20% PEG3350, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.54 Å R-free 0.264 |
| 2GTK Structure-based Design of Indole Propionic Acids as Novel PPARag CO-Agonists Deposited 2006-04-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
|
Not recorded | 208 (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.1M TRIS, PEG 3350, 0.2M MGSO4, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.10 Å R-free 0.261 |
| 2HWQ Structural basis for the structure-activity relationships of Peroxisome Proliferator-Activated Receptor agonists Deposited 2006-08-01 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
235–505（271 aa）
Fragment：Ligand binding domain
Chain B
235–505（271 aa）
Fragment：Ligand binding domain
|
Not recorded | DRY [(1-{3-[(6-BENZOYL-1-PROPYL-2-NAPHTHYL)OXY]PROPYL}-1H-INDOL-5-YL)OXY]ACETIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；28.25% PEG3350, 0.016M sodium citrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.97 Å R-free 0.265 |
| 2HWR Structural basis for the structure-activity relationships of Peroxisome Proliferator-Activated Receptor agonists Deposited 2006-08-01 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
235–505（271 aa）
Fragment：Ligand binding domain
Chain B
235–505（271 aa）
Fragment：Ligand binding domain
|
Not recorded | DRD 2-[(1-{3-[(6-BENZOYL-1-PROPYL-2-NAPHTHYL)OXY]PROPYL}-1H-INDOL-4-YL)OXY]-2-METHYLPROPANOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；28% PEG3350, 0.016M sodium citrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.34 Å R-free 0.316 |
| 2I4J Crystal structure of the complex between PPARgamma and the agonist LT160 (ureidofibrate derivative) Deposited 2006-08-22 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain (LBD), residues 223-504
Chain B
223–504（282 aa）
Fragment：ligand binding domain (LBD), residues 223-504
|
Not recorded | DRJ (2R)-2-(4-{2-[1,3-BENZOXAZOL-2-YL(HEPTYL)AMINO]ETHYL}PHENOXY)-2-METHYLBUTANOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8 M NaCitrate, 0.15 M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.10 Å R-free 0.278 |
| 2I4P Crystal structure of the complex between PPARgamma and the partial agonist LT127 (ureidofibrate derivative). Structure obtained from crystals of the apo-form soaked for 30 days. Deposited 2006-08-22 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain (LBD)
Chain B
223–504（282 aa）
Fragment：ligand binding domain (LBD)
|
Not recorded | DRH (2S)-2-(4-{2-[1,3-BENZOXAZOL-2-YL(HEPTYL)AMINO]ETHYL}PHENOXY)-2-METHYLBUTANOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8 M NaCitrate, 0.15 M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.10 Å R-free 0.295 |
| 2I4Z Crystal structure of the complex between PPARgamma and the partial agonist LT127 (ureidofibrate derivative). This structure has been obtained from crystals soaked for 6 hours. Deposited 2006-08-23 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain (LBD), residues 223-504
Chain B
223–504（282 aa）
Fragment：ligand binding domain (LBD), residues 223-504
|
Not recorded | DRH (2S)-2-(4-{2-[1,3-BENZOXAZOL-2-YL(HEPTYL)AMINO]ETHYL}PHENOXY)-2-METHYLBUTANOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8 M NaCitrate, 0.15 M Tris.
Crystals of the apo-form have been soaked for 6 hours in a solution containing the ligand, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.25 Å R-free 0.290 |
| 2OM9 Ajulemic acid, a synthetic cannabinoid bound to PPAR gamma Deposited 2007-01-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
232–505（274 aa）
Fragment：Ligand binding domain, residues 232-505
|
Not recorded | AJA (6AR,10AR)-3-(1,1-DIMETHYLHEPTYL)-1-HYDROXY-6,6-DIMETHYL-6A,7,10,10A-TETRAHYDRO-6H-BENZO[C]CHROMENE-9-CARBOXYLIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
283 K；4M sodium formate, VAPOR DIFFUSION, HANGING DROP, temperature 283K
|
Resolution 2.80 Å R-free 0.267 |
| 2OM9 Ajulemic acid, a synthetic cannabinoid bound to PPAR gamma Deposited 2007-01-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
232–505（274 aa）
Fragment：Ligand binding domain, residues 232-505
|
Not recorded | AJA (6AR,10AR)-3-(1,1-DIMETHYLHEPTYL)-1-HYDROXY-6,6-DIMETHYL-6A,7,10,10A-TETRAHYDRO-6H-BENZO[C]CHROMENE-9-CARBOXYLIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
283 K；4M sodium formate, VAPOR DIFFUSION, HANGING DROP, temperature 283K
|
Resolution 2.80 Å R-free 0.267 |
| 2OM9 Ajulemic acid, a synthetic cannabinoid bound to PPAR gamma Deposited 2007-01-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
232–505（274 aa）
Fragment：Ligand binding domain, residues 232-505
|
Not recorded | AJA (6AR,10AR)-3-(1,1-DIMETHYLHEPTYL)-1-HYDROXY-6,6-DIMETHYL-6A,7,10,10A-TETRAHYDRO-6H-BENZO[C]CHROMENE-9-CARBOXYLIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
283 K；4M sodium formate, VAPOR DIFFUSION, HANGING DROP, temperature 283K
|
Resolution 2.80 Å R-free 0.267 |
| 2OM9 Ajulemic acid, a synthetic cannabinoid bound to PPAR gamma Deposited 2007-01-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain D
232–505（274 aa）
Fragment：Ligand binding domain, residues 232-505
|
Not recorded | AJA (6AR,10AR)-3-(1,1-DIMETHYLHEPTYL)-1-HYDROXY-6,6-DIMETHYL-6A,7,10,10A-TETRAHYDRO-6H-BENZO[C]CHROMENE-9-CARBOXYLIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
283 K；4M sodium formate, VAPOR DIFFUSION, HANGING DROP, temperature 283K
|
Resolution 2.80 Å R-free 0.267 |
| 2P4Y Crystal structure of human PPAR-gamma-ligand binding domain complexed with an indole-based modulator Deposited 2007-03-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Fragment：Ligand-binding Domain (LBD), Residues 231-505
Chain B
231–505（275 aa）
Fragment：Ligand-binding Domain (LBD), Residues 231-505
|
Not recorded | C03 (2R)-2-(4-CHLORO-3-{[3-(6-METHOXY-1,2-BENZISOXAZOL-3-YL)-2-METHYL-6-(TRIFLUOROMETHOXY)-1H-INDOL-1-YL]METHYL}PHENOXY)PROPANOIC ACID × 2 TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；0.95M Trisodium citrate, 0.1M Tris-HCl pH 8.5, 1mM TCEP, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.25 Å R-free 0.274 |
| 2POB PPARgamma Ligand binding domain complexed with a farglitazar analogue gw4709 Deposited 2007-04-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Fragment：Ligand binding domain
Chain B
234–505（272 aa）
Fragment：Ligand binding domain
|
Not recorded | GW4 N-[(2S)-2-[(2-BENZOYLPHENYL)AMINO]-3-{4-[2-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)ETHOXY]PHENYL}PROPYL]ACETAMIDE × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100mM Hepes and 1.4M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.30 Å R-free 0.273 |
| 2PRG LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA Deposited 1998-08-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
205–475（271 aa）
Fragment：LBD (LIGAND BINDING DOMAIN), RESIDUES 207-477
|
Not recorded | BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 2.30 Å R-free 0.264 |
| 2PRG LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA Deposited 1998-08-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
205–475（271 aa）
Fragment：LBD (LIGAND BINDING DOMAIN), RESIDUES 207-477
|
Not recorded | BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 2.30 Å R-free 0.264 |
| 2Q59 Crystal Structure of PPARgamma LBD bound to full agonist MRL20 Deposited 2007-05-31 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
233–505（273 aa）
Fragment：Ligand binding domain
Chain B
233–505（273 aa）
Fragment：Ligand binding domain
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 240 (2S)-2-(2-{[1-(4-METHOXYBENZOYL)-2-METHYL-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL]METHYL}PHENOXY)PROPANOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；1.4 M sodium citrate, 0.125 M Tris 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.20 Å R-free 0.230 |
| 2Q5P Crystal Structure of PPARgamma bound to partial agonist MRL24 Deposited 2007-06-01 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
233–505（273 aa）
Fragment：Ligand binding domain
Chain B
233–505（273 aa）
Fragment：Ligand binding domain
|
Not recorded | 241 (2S)-2-(3-{[1-(4-METHOXYBENZOYL)-2-METHYL-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL]METHYL}PHENOXY)PROPANOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；1.4M sodium citrate, 0.125M Tris 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.30 Å R-free 0.247 |
| 2Q5S Crystal Structure of PPARgamma bound to partial agonist nTZDpa Deposited 2007-06-01 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
233–505（273 aa）
Fragment：Ligand binding domain
Chain B
233–505（273 aa）
Fragment：Ligand binding domain
|
Not recorded | NZA 5-CHLORO-1-(4-CHLOROBENZYL)-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；1.4M sodium citrate, 0.125M Tris8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.05 Å R-free 0.245 |
| 2Q61 Crystal Structure of PPARgamma ligand binding domain bound to partial agonist SR145 Deposited 2007-06-04 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
233–505（273 aa）
Fragment：Ligand binding domain
Chain B
233–505（273 aa）
Fragment：Ligand binding domain
|
Not recorded | SF1 1-BENZYL-5-CHLORO-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；1.4M sodium citrate, 0.125M Tris 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.20 Å R-free 0.229 |
| 2Q6R Crystal structure of PPAR gamma complexed with partial agonist SF147 Deposited 2007-06-01 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
233–505（273 aa）
Fragment：Ligand binding domain
Chain B
233–505（273 aa）
Fragment：Ligand binding domain
|
Not recorded | SF2 5-CHLORO-1-(3-METHOXYBENZYL)-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；1.4M sodium citrate, 0.125M Tris 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.41 Å R-free 0.284 |
| 2Q6S 2.4 angstrom crystal structure of PPAR gamma complexed to BVT.13 without co-activator peptides Deposited 2007-06-01 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
233–505（273 aa）
Fragment：Ligand binding domain
Chain B
233–505（273 aa）
Fragment：Ligand binding domain
|
Not recorded | PLB 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；1.4M sodium citrate, 0.125 M Tris 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.40 Å R-free 0.264 |
| 2Q8S X-ray Crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a PPAR gamma/alpha dual agonist Deposited 2007-06-11 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：Ligand binding domain (residue 235-505)
Chain B
235–505（271 aa）
Fragment：Ligand binding domain (residue 235-505)
|
Not recorded | L92 (2S)-3-{4-[3-(5-METHYL-2-PHENYL-1,3-OXAZOL-4-YL)PROPYL]PHENYL}-2-(1H-PYRROL-1-YL)PROPANOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；100 mM Immidizole, 860 mM Sodium Citrate, Glycerol 5 % (v/v) , pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å R-free 0.282 |
| 2QMV High Resolution Structure of Peroxisone Proliferation-Activated Receptor gamma and Characterisation of its Interaction with the Co-activator Transcriptional Intermediary Factor 2 Deposited 2007-07-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
235–504（270 aa）
Fragment：Ligand Binding Domain, residues 235-504
|
Not recorded | No recorded non-water small molecule | SOLUTION NMR mmCIF provides none of the parsed conditions | Resolution not provided |
| 2VSR hPPARgamma Ligand binding domain in complex with 9-(S)-HODE Deposited 2008-04-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
202–475（274 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
|
Not recorded | 9HO (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；pH 8
|
Resolution 2.05 Å R-free 0.266 |
| 2VSR hPPARgamma Ligand binding domain in complex with 9-(S)-HODE Deposited 2008-04-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
202–475（274 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
|
Not recorded | 9HO (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；pH 8
|
Resolution 2.05 Å R-free 0.266 |
| 2VST hPPARgamma Ligand binding domain in complex with 13-(S)-HODE Deposited 2008-04-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
202–475（274 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
|
Not recorded | 243 (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；pH 8
|
Resolution 2.35 Å R-free 0.274 |
| 2VST hPPARgamma Ligand binding domain in complex with 13-(S)-HODE Deposited 2008-04-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
202–475（274 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
|
Not recorded | 243 (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；pH 8
|
Resolution 2.35 Å R-free 0.274 |
| 2VV0 hPPARgamma Ligand binding domain in complex with DHA Deposited 2008-06-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
202–475（274 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
|
Not recorded | HXA DOCOSA-4,7,10,13,16,19-HEXAENOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；295 K；PH 8, TRIS 100MM, 0.7M NACITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELSIUS
|
Resolution 2.55 Å R-free 0.261 |
| 2VV0 hPPARgamma Ligand binding domain in complex with DHA Deposited 2008-06-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
202–475（274 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
|
Not recorded | HXA DOCOSA-4,7,10,13,16,19-HEXAENOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；295 K；PH 8, TRIS 100MM, 0.7M NACITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELSIUS
|
Resolution 2.55 Å R-free 0.261 |
| 2VV1 hPPARgamma Ligand binding domain in complex with 4-HDHA Deposited 2008-06-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
202–475（274 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
|
Not recorded | 4HD (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；295 K；PH 8, TRIS 100MM, 0.7M NACITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELSIUS
|
Resolution 2.20 Å R-free 0.277 |
| 2VV1 hPPARgamma Ligand binding domain in complex with 4-HDHA Deposited 2008-06-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
202–475（274 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
|
Not recorded | 4HD (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；295 K；PH 8, TRIS 100MM, 0.7M NACITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELSIUS
|
Resolution 2.20 Å R-free 0.277 |
| 2VV2 hPPARgamma Ligand binding domain in complex with 5-HEPA Deposited 2008-06-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
202–475（274 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
|
Not recorded | 5HE (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；295 K；PH 8, TRIS 100MM, 0.7M NA CITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELCIUS
|
Resolution 2.75 Å R-free 0.263 |
| 2VV2 hPPARgamma Ligand binding domain in complex with 5-HEPA Deposited 2008-06-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
202–475（274 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
|
Not recorded | 5HE (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；295 K；PH 8, TRIS 100MM, 0.7M NA CITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELCIUS
|
Resolution 2.75 Å R-free 0.263 |
| 2VV3 hPPARgamma Ligand binding domain in complex with 4-oxoDHA Deposited 2008-06-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
202–475（274 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
|
Not recorded | 4R8 (6E,10Z,13Z,16Z,19Z)-4-oxodocosa-6,10,13,16,19-pentaenoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；295 K；TRIS 100MM PH 8, 0.7M NA-CITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELSIUS
|
Resolution 2.85 Å R-free 0.252 |
| 2VV3 hPPARgamma Ligand binding domain in complex with 4-oxoDHA Deposited 2008-06-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
202–475（274 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；295 K；TRIS 100MM PH 8, 0.7M NA-CITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELSIUS
|
Resolution 2.85 Å R-free 0.252 |
| 2VV4 hPPARgamma Ligand binding domain in complex with 6-oxoOTE Deposited 2008-06-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
202–475（274 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
|
Not recorded | 6OC (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；295 K；PH 8, TRIS 100MM, 0.7M NACITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELSIUS
|
Resolution 2.35 Å R-free 0.252 |
| 2VV4 hPPARgamma Ligand binding domain in complex with 6-oxoOTE Deposited 2008-06-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
202–475（274 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 202-475
|
Not recorded | 6OB (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8；295 K；PH 8, TRIS 100MM, 0.7M NACITRATE, 1MM TCEP, 0.5MM EDTA, VAPOUR DIFFUSION, DARK, UNDER NITROGEN, 22 DEGREES CELSIUS
|
Resolution 2.35 Å R-free 0.252 |
| 2XKW LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST PIOGLITAZONE Deposited 2010-07-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
204–477（274 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 204-477
|
Not recorded | P1B (5R)-5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione × 1 PE4 2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；292 K；PROTEIN CONC. 17MG/ML, 50 MM TRIS PH 8.0,0.1M NACL, 0.5 MM DTT, 2 MM EDTA. RESERVOIR: 20% PEG4000,10% ISOPROPANOL, 0.1M HEPES PH 7.5 , VAPOR DIFFUSION,TEMPERATURE 292K
|
Resolution 2.02 Å R-free 0.202 |
| 2XKW LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN COMPLEX WITH THE AGONIST PIOGLITAZONE Deposited 2010-07-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
204–477（274 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 204-477
|
Not recorded | P1B (5R)-5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；292 K；PROTEIN CONC. 17MG/ML, 50 MM TRIS PH 8.0,0.1M NACL, 0.5 MM DTT, 2 MM EDTA. RESERVOIR: 20% PEG4000,10% ISOPROPANOL, 0.1M HEPES PH 7.5 , VAPOR DIFFUSION,TEMPERATURE 292K
|
Resolution 2.02 Å R-free 0.202 |
| 2YFE Ligand binding domain of human PPAR gamma in complex with amorfrutin 1 Deposited 2011-04-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
195–477（283 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 195-477
|
Not recorded | YFE Amorfrutin 1 × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；0.8M TRI-SODIUM CITRATE, 0.1M IMIDAZOLE, PH 8.0
|
Resolution 2.00 Å R-free 0.254 |
| 2YFE Ligand binding domain of human PPAR gamma in complex with amorfrutin 1 Deposited 2011-04-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
195–477（283 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 195-477
|
Not recorded | YFE Amorfrutin 1 × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；0.8M TRI-SODIUM CITRATE, 0.1M IMIDAZOLE, PH 8.0
|
Resolution 2.00 Å R-free 0.254 |
| 2ZK0 Human peroxisome proliferator-activated receptor gamma ligand binding domain Deposited 2008-03-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain
Chain B
223–504（282 aa）
Fragment：ligand binding domain
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.36 Å R-free 0.313 |
| 2ZK0 Human peroxisome proliferator-activated receptor gamma ligand binding domain Deposited 2008-03-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain
Chain B
223–504（282 aa）
Fragment：ligand binding domain
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.36 Å R-free 0.313 |
| 2ZK1 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 15-deoxy-delta12,14-prostaglandin J2 Deposited 2008-03-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain
Chain B
223–504（282 aa）
Fragment：ligand binding domain
|
Not recorded | PTG (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.61 Å R-free 0.307 |
| 2ZK1 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 15-deoxy-delta12,14-prostaglandin J2 Deposited 2008-03-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain
Chain B
223–504（282 aa）
Fragment：ligand binding domain
|
Not recorded | PTG (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.61 Å R-free 0.307 |
| 2ZK2 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with glutathion conjugated 15-deoxy-delta12,14-prostaglandin J2 Deposited 2008-03-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain
Chain B
223–504（282 aa）
Fragment：ligand binding domain
|
Not recorded | GSH Glutathione × 1 PTG (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.26 Å R-free 0.299 |
| 2ZK2 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with glutathion conjugated 15-deoxy-delta12,14-prostaglandin J2 Deposited 2008-03-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain
Chain B
223–504（282 aa）
Fragment：ligand binding domain
|
Not recorded | GSH Glutathione × 1 PTG (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.26 Å R-free 0.299 |
| 2ZK3 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 8-oxo-eicosatetraenoic acid Deposited 2008-03-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain
Chain B
223–504（282 aa）
Fragment：ligand binding domain
|
Not recorded | OCX (5E,11E,14E)-8-oxoicosa-5,9,11,14-tetraenoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.58 Å R-free 0.299 |
| 2ZK3 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 8-oxo-eicosatetraenoic acid Deposited 2008-03-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain
Chain B
223–504（282 aa）
Fragment：ligand binding domain
|
Not recorded | OCX (5E,11E,14E)-8-oxoicosa-5,9,11,14-tetraenoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.58 Å R-free 0.299 |
| 2ZK4 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 15-oxo-eicosatetraenoic acid Deposited 2008-03-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain
Chain B
223–504（282 aa）
Fragment：ligand binding domain
|
Not recorded | OCR (5E,8E,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.57 Å R-free 0.306 |
| 2ZK4 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with 15-oxo-eicosatetraenoic acid Deposited 2008-03-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain
Chain B
223–504（282 aa）
Fragment：ligand binding domain
|
Not recorded | OCR (5E,8E,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.57 Å R-free 0.306 |
| 2ZK5 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with nitro-233 Deposited 2008-03-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain
Chain B
223–504（282 aa）
Fragment：ligand binding domain
|
Not recorded | NRO 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.45 Å R-free 0.306 |
| 2ZK5 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with nitro-233 Deposited 2008-03-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain
Chain B
223–504（282 aa）
Fragment：ligand binding domain
|
Not recorded | NRO 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.45 Å R-free 0.306 |
| 2ZK6 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with C8-BODIPY Deposited 2008-03-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain
Chain B
223–504（282 aa）
Fragment：ligand binding domain
|
Not recorded | C08 difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.41 Å R-free 0.299 |
| 2ZK6 Human peroxisome proliferator-activated receptor gamma ligand binding domain complexed with C8-BODIPY Deposited 2008-03-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain
Chain B
223–504（282 aa）
Fragment：ligand binding domain
|
Not recorded | C08 difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium Citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.41 Å R-free 0.299 |
| 2ZNO Human PPAR gamma ligand binding domain in complex with a synthetic agonist TIPP703 Deposited 2008-04-30 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：Ligand binding domain
Chain B
223–504（282 aa）
Fragment：Ligand binding domain
|
Not recorded | S44 (2S)-2-(4-propoxy-3-{[({4-[(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]dec-1-yl]phenyl}carbonyl)amino]methyl}benzyl)butanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M Sodium citrate, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å R-free 0.286 |
| 2ZNO Human PPAR gamma ligand binding domain in complex with a synthetic agonist TIPP703 Deposited 2008-04-30 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：Ligand binding domain
Chain B
223–504（282 aa）
Fragment：Ligand binding domain
|
Not recorded | S44 (2S)-2-(4-propoxy-3-{[({4-[(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]dec-1-yl]phenyl}carbonyl)amino]methyl}benzyl)butanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M Sodium citrate, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å R-free 0.286 |
| 2ZVT Cys285Ser mutant PPARgamma ligand-binding domain complexed with 15-deoxy-delta12,14-prostaglandin J2 Deposited 2008-11-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：Ligand-binding domain
Chain B
223–504（282 aa）
Fragment：Ligand-binding domain
|
Mutation：C285S Mutation：C285S | PTG (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M Hepes, 0.8M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.275 |
| 2ZVT Cys285Ser mutant PPARgamma ligand-binding domain complexed with 15-deoxy-delta12,14-prostaglandin J2 Deposited 2008-11-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：Ligand-binding domain
Chain B
223–504（282 aa）
Fragment：Ligand-binding domain
|
Mutation：C285S Mutation：C285S | PTG (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M Hepes, 0.8M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.275 |
| 3ADS Human PPARgamma ligand-binding domain in complex with indomethacin Deposited 2010-01-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
Chain B
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
|
Not recorded | IMN INDOMETHACIN × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.25 Å R-free 0.277 |
| 3ADS Human PPARgamma ligand-binding domain in complex with indomethacin Deposited 2010-01-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
Chain B
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
|
Not recorded | IMN INDOMETHACIN × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.25 Å R-free 0.277 |
| 3ADT Human PPARgamma ligand-binding domain in complex with 5-hydroxy-indole acetate Deposited 2010-01-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
Chain B
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
|
Not recorded | HID (5-hydroxy-1H-indol-3-yl)acetic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.70 Å R-free 0.283 |
| 3ADT Human PPARgamma ligand-binding domain in complex with 5-hydroxy-indole acetate Deposited 2010-01-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
Chain B
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
|
Not recorded | HID (5-hydroxy-1H-indol-3-yl)acetic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.70 Å R-free 0.283 |
| 3ADU Human PPARgamma ligand-binding domain in complex with 5-methoxy-indole acetate Deposited 2010-01-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
Chain B
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
|
Not recorded | MYI (5-methoxy-1H-indol-3-yl)acetic acid × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.77 Å R-free 0.276 |
| 3ADU Human PPARgamma ligand-binding domain in complex with 5-methoxy-indole acetate Deposited 2010-01-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
Chain B
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
|
Not recorded | MYI (5-methoxy-1H-indol-3-yl)acetic acid × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.77 Å R-free 0.276 |
| 3ADV Human PPARgamma ligand-binding domain in complex with serotonin Deposited 2010-01-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
Chain B
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
|
Not recorded | SRO SEROTONIN × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.27 Å R-free 0.267 |
| 3ADV Human PPARgamma ligand-binding domain in complex with serotonin Deposited 2010-01-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
Chain B
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
|
Not recorded | SRO SEROTONIN × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.27 Å R-free 0.267 |
| 3ADW Human PPARgamma ligand-binding domain in complex with 5-methoxy-indole acetate and 15-oxo-eicosatetraenoic acid Deposited 2010-01-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
Chain B
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
|
Not recorded | MYI (5-methoxy-1H-indol-3-yl)acetic acid × 1 OCR (5E,8E,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.07 Å R-free 0.265 |
| 3ADW Human PPARgamma ligand-binding domain in complex with 5-methoxy-indole acetate and 15-oxo-eicosatetraenoic acid Deposited 2010-01-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
Chain B
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
|
Not recorded | MYI (5-methoxy-1H-indol-3-yl)acetic acid × 1 OCR (5E,8E,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.07 Å R-free 0.265 |
| 3ADX Human PPARgamma ligand-binding domain in complex with indomethacin and nitro-233 Deposited 2010-01-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
Chain B
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
|
Not recorded | NRO 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid × 1 IMN INDOMETHACIN × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.95 Å R-free 0.275 |
| 3ADX Human PPARgamma ligand-binding domain in complex with indomethacin and nitro-233 Deposited 2010-01-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
Chain B
223–505（283 aa）
Fragment：ligand-binding domain, residues in UNP 223-505
|
Not recorded | NRO 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid × 1 IMN INDOMETHACIN × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.1M HEPES, 0.8M Sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.95 Å R-free 0.275 |
| 3AN3 Human PPAR gamma ligand binding domain in complex with a gamma selective agonist MO3S Deposited 2010-08-30 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：Ligand binding domain
Chain B
223–504（282 aa）
Fragment：Ligand binding domain
|
Not recorded | M7S (2S)-2-benzyl-3-(4-propoxy-3-{[({4-[(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]dec-1-yl]phenyl}carbonyl)amino]methyl}phenyl)propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å R-free 0.278 |
| 3AN3 Human PPAR gamma ligand binding domain in complex with a gamma selective agonist MO3S Deposited 2010-08-30 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：Ligand binding domain
Chain B
223–504（282 aa）
Fragment：Ligand binding domain
|
Not recorded | M7S (2S)-2-benzyl-3-(4-propoxy-3-{[({4-[(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]dec-1-yl]phenyl}carbonyl)amino]methyl}phenyl)propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å R-free 0.278 |
| 3AN4 Human PPAR gamma ligand binding domain in complex with a gamma selective agonist MO4R Deposited 2010-08-30 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：Ligand binding domain
Chain B
223–504（282 aa）
Fragment：Ligand binding domain
|
Not recorded | M7R (2R)-2-benzyl-3-(4-propoxy-3-{[({4-[(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]dec-1-yl]phenyl}carbonyl)amino]methyl}phenyl)propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å R-free 0.288 |
| 3AN4 Human PPAR gamma ligand binding domain in complex with a gamma selective agonist MO4R Deposited 2010-08-30 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：Ligand binding domain
Chain B
223–504（282 aa）
Fragment：Ligand binding domain
|
Not recorded | M7R (2R)-2-benzyl-3-(4-propoxy-3-{[({4-[(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]dec-1-yl]phenyl}carbonyl)amino]methyl}phenyl)propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å R-free 0.288 |
| 3B0Q Human PPAR gamma ligand binding domain in complex with MCC555 Deposited 2011-06-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–504（274 aa）
Fragment：UNP RESIDUES 231-504
Chain B
231–504（274 aa）
Fragment：UNP RESIDUES 231-504
|
Not recorded | MC5 (5S)-5-({6-[(2-fluorobenzyl)oxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M Sodium Citrate, 0.1M Hepes (pH7.5), VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.10 Å R-free 0.229 |
| 3B0R Human PPAR gamma ligand binding dmain complexed with GW9662 in a covalent bonded form Deposited 2011-06-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–504（274 aa）
Fragment：UNP RESIDUES 231-504
Chain B
231–504（274 aa）
Fragment：UNP RESIDUES 231-504
|
Not recorded | GW9 2-chloro-5-nitro-N-phenylbenzamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M sodium citrate, 0.1M Hepes (pH7.5), VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.15 Å R-free 0.249 |
| 3B1M Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Cerco-A Deposited 2011-07-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Fragment：ligand binding domain, UNP residues 234-505
|
Not recorded | KRC (9aS)-8-acetyl-N-[(2-ethylnaphthalen-1-yl)methyl]-1,7-dihydroxy-3-methoxy-9a-methyl-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, sodium thiocyanate, Tris-hydrochloride, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 1.60 Å R-free 0.244 |
| 3B3K Crystal structure of the complex between PPARgamma and the full agonist LT175 Deposited 2007-10-22 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：UNP residues 223-504
Chain B
223–504（282 aa）
Fragment：UNP residues 223-504
|
Not recorded | LRG (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris, pH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.60 Å R-free 0.316 |
| 3B3K Crystal structure of the complex between PPARgamma and the full agonist LT175 Deposited 2007-10-22 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：UNP residues 223-504
Chain B
223–504（282 aa）
Fragment：UNP residues 223-504
|
Not recorded | LRG (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris, pH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.60 Å R-free 0.316 |
| 3BC5 X-ray crystal structure of human ppar gamma with 2-(5-(3-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzyl)-2-phenyl-2h-1,2,3-triazol-4-yl)acetic acid Deposited 2007-11-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
Fragment：ligand binding domain
|
Not recorded | ZAA (5-{3-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzyl}-2-phenyl-2H-1,2,3-triazol-4-yl)acetic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294 K；2.4M Na-Formate, 0.3M ammonium acetate, pH 7.5, vapor diffusion, hanging drop, temperature 294K
|
Resolution 2.27 Å R-free 0.249 |
| 3CDP Crystal structure of PPAR-gamma LBD complexed with a partial agonist, analogue of clofibric acid Deposited 2008-02-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain (LBD), UNP residues 223-504
Chain B
223–504（282 aa）
Fragment：ligand binding domain (LBD), UNP residues 223-504
|
Not recorded | YRG (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15mM Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.80 Å R-free 0.298 |
| 3CDP Crystal structure of PPAR-gamma LBD complexed with a partial agonist, analogue of clofibric acid Deposited 2008-02-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain (LBD), UNP residues 223-504
|
Not recorded | YRG (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15mM Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.80 Å R-free 0.298 |
| 3CDP Crystal structure of PPAR-gamma LBD complexed with a partial agonist, analogue of clofibric acid Deposited 2008-02-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
223–504（282 aa）
Fragment：ligand binding domain (LBD), UNP residues 223-504
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15mM Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.80 Å R-free 0.298 |
| 3CDS Crystal structure of the complex between PPAR-gamma and the agonist LT248 (clofibric acid analogue) Deposited 2008-02-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain (LBD), UNP residues 223-504
Chain B
223–504（282 aa）
Fragment：ligand binding domain (LBD), UNP residues 223-504
|
Not recorded | GRR (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15mM Tris, pH 8.000, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.65 Å R-free 0.319 |
| 3CDS Crystal structure of the complex between PPAR-gamma and the agonist LT248 (clofibric acid analogue) Deposited 2008-02-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain (LBD), UNP residues 223-504
|
Not recorded | GRR (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15mM Tris, pH 8.000, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.65 Å R-free 0.319 |
| 3CDS Crystal structure of the complex between PPAR-gamma and the agonist LT248 (clofibric acid analogue) Deposited 2008-02-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
223–504（282 aa）
Fragment：ligand binding domain (LBD), UNP residues 223-504
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15mM Tris, pH 8.000, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.65 Å R-free 0.319 |
| 3CS8 Structural and Biochemical Basis for the Binding Selectivity of PPARg to PGC-1a Deposited 2008-04-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–504（271 aa）
Fragment：LBD domain (UNP residues 234-504)
|
Not recorded | SO4 SULFATE ION × 4 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.2；298 K；20% PEG3350, 0.2M Ammonium Iodide, pH 6.2, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.30 Å R-free 0.282 |
| 3CWD Molecular recognition of nitro-fatty acids by PPAR gamma Deposited 2008-04-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
236–505（270 aa）
Fragment：PPAR gamma LBD domain
|
Not recorded | LNA (9E,12Z)-10-nitrooctadeca-9,12-dienoic acid × 1 LNB (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.40 Å R-free 0.290 |
| 3CWD Molecular recognition of nitro-fatty acids by PPAR gamma Deposited 2008-04-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
236–505（270 aa）
Fragment：PPAR gamma LBD domain
|
Not recorded | LNA (9E,12Z)-10-nitrooctadeca-9,12-dienoic acid × 1 LNB (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.40 Å R-free 0.290 |
| 3D6D Crystal Structure of the complex between PPARgamma LBD and the LT175(R-enantiomer) Deposited 2008-05-19 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain (LBD), UNP residues 223-504
Chain B
223–504（282 aa）
Fragment：ligand binding domain (LBD), UNP residues 223-504
|
Not recorded | LRG (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris, pH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.40 Å R-free 0.305 |
| 3D6D Crystal Structure of the complex between PPARgamma LBD and the LT175(R-enantiomer) Deposited 2008-05-19 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain (LBD), UNP residues 223-504
Chain B
223–504（282 aa）
Fragment：ligand binding domain (LBD), UNP residues 223-504
|
Not recorded | LRG (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris, pH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.40 Å R-free 0.305 |
| 3DZU Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with BVT.13, 9-cis Retinoic Acid and NCOA2 Peptide Deposited 2008-07-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: hexameric |
Chain D
102–505（404 aa）
Fragment：UNP residues 102-505
|
Not recorded | ZN ZINC ION × 4 9CR (9cis)-retinoic acid × 1 PLB 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；15-18% PEG 3350, 25mM MgCl2, 100mM NH4Cl, 5mM DTT and 0.1M MES, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 3.20 Å R-free 0.272 |
| 3DZY Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with Rosiglitazone, 9-cis Retinoic Acid and NCOA2 Peptide Deposited 2008-07-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: hexameric |
Chain D
102–505（404 aa）
Fragment：UNP residues 102-505
|
Not recorded | 9CR (9cis)-retinoic acid × 1 ZN ZINC ION × 4 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；15-18% PEG 3350, 25mM MgCl2, 100mM NH4Cl, 5mM DTT and 0.1M MES, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 3.10 Å R-free 0.268 |
| 3E00 Intact PPAR gamma - RXR alpha Nuclear Receptor Complex on DNA bound with GW9662, 9-cis Retinoic Acid and NCOA2 Peptide Deposited 2008-07-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Heteromer；Protein × 4 PDB declaration: hexameric |
Chain D
102–505（404 aa）
Fragment：UNP residues 102-505
|
Not recorded | ZN ZINC ION × 4 9CR (9cis)-retinoic acid × 1 GW9 2-chloro-5-nitro-N-phenylbenzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；277 K；15-18% PEG 3350, 25mM MgCl2, 100mM NH4Cl, 5mM DTT and 0.1M MES, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 3.10 Å R-free 0.276 |
| 3ET0 Structure of PPARgamma with 3-(5-Methoxy-1H-indol-3-yl)-propionic acid Deposited 2008-10-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | ET0 3-(5-methoxy-1H-indol-3-yl)propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；The purified PPARg ligand binding domain (LBD) protein was diluated to 12 mg/ml and 1mM of compound 1 was added to the protein prior to crystallization by mixing equal volumes of protein/compound sample with reservoir solution containing 0.9 M sodium citrate and 0.1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) at pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.40 Å R-free 0.255 |
| 3ET0 Structure of PPARgamma with 3-(5-Methoxy-1H-indol-3-yl)-propionic acid Deposited 2008-10-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | GLC alpha-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；The purified PPARg ligand binding domain (LBD) protein was diluated to 12 mg/ml and 1mM of compound 1 was added to the protein prior to crystallization by mixing equal volumes of protein/compound sample with reservoir solution containing 0.9 M sodium citrate and 0.1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) at pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.40 Å R-free 0.255 |
| 3ET3 Structure of PPARgamma with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid Deposited 2008-10-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN
|
Not recorded | ET1 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5；277 K；The purified PPARg LBD protein was diluted to 12 mg/ml and 1mM of indeglitazar and 2x molar excess of SRC-1 peptide were added prior to crystallization by mixing equal volumes of protein/compound sample with reservoir solution containing 27% polyethylene glycol (PEG) 4000, 0.1 M 2-(bis-(2-hydroxy-ethyl)-amino)-2-hydroxymethyl- propane-1,3-diol (BisTris) buffer at pH 6.5, 0.2 M ammonium acetate, and 5% glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.95 Å R-free 0.236 |
| 3FEJ Design and biological evaluation of novel, balanced dual PPARa/g agonists Deposited 2008-11-30 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：PPAR gamma ligand binding domain
|
Not recorded | CTM (2S)-3-(4-{[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methoxy}-2-methylphenyl)-2-ethoxypropanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.1M Tris, 15-20% PEG3350, 10% Glycerol, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.01 Å R-free 0.250 |
| 3FUR Crystal Structure of PPARg in complex with INT131 Deposited 2009-01-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Fragment：LBD (ligand binding domain), UNP residues 234-505
|
Not recorded | Z12 2,4-dichloro-N-[3,5-dichloro-4-(quinolin-3-yloxy)phenyl]benzenesulfonamide × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；298 K；30% PEG 4000, 0.2M MgCl2, Tris-HCl 8.5, vapor diffusion, hanging drop, temperature 298K
|
Resolution 2.30 Å R-free 0.242 |
| 3G9E Aleglitaar. a new. potent, and balanced dual ppara/g agonist for the treatment of type II diabetes Deposited 2009-02-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN
|
Not recorded | RO7 (2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293 K；0.2M NaK TARTRATE, 25% PEG 3350, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å R-free 0.262 |
| 3GBK Crystal Structure of Human PPAR-gamma Ligand Binding Domain Complexed with a Potent and Selective Agonist Deposited 2009-02-19 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：ligand binding domian, UNP residues 235-505
Chain B
235–505（271 aa）
Fragment：ligand binding domian, UNP residues 235-505
|
Not recorded | 2PQ 2-[(1-{3-[4-(biphenyl-4-ylcarbonyl)-2-propylphenoxy]propyl}-1,2,3,4-tetrahydroquinolin-5-yl)oxy]-2-methylpropanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；28.25% PEG 3350. 0.016M sodium citrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.30 Å R-free 0.298 |
| 3H0A Crystal Structure of Peroxisome Proliferator-Activated Receptor Gamma (PPARg) and Retinoic Acid Receptor Alpha (RXRa) in Complex with 9-cis Retinoic Acid, Co-activator Peptide, and a Partial Agonist Deposited 2009-04-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain D
234–505（272 aa）
Fragment：UNP RESIDUES 234-505
|
Not recorded | 9RA 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid × 1 D30 [(4-{[2-(pent-2-yn-1-yloxy)-4-{[4-(trifluoromethyl)phenoxy]methyl}phenyl]sulfanyl}-5,6,7,8-tetrahydronaphthalen-1-yl)oxy]acetic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；289 K；25% PEG 2000 monomethyl ether, 0.3 M sodium acetate, 0.1 M Hepes 7.5, vapor diffusion, temperature 289K
|
Resolution 2.10 Å R-free 0.342 |
| 3HO0 Crystal structure of the PPARgamma-LBD complexed with a new aryloxy-3phenylpropanoic acid Deposited 2009-06-01 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain (LBD), UNP residues 223-504
Chain B
223–504（282 aa）
Fragment：ligand binding domain (LBD), UNP residues 223-504
|
Not recorded | DKD (2S)-2-(4-phenethylphenoxy)-3-phenyl-propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris, pH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.60 Å R-free 0.328 |
| 3HOD Crystal structure of the PPARgamma-LBD complexed with a new aryloxy-3phenylpropanoic acid Deposited 2009-06-02 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：ligand binding domain (LBD), UNP residues 223-504
Chain B
223–504（282 aa）
Fragment：ligand binding domain (LBD), UNP residues 223-504
|
Not recorded | ZZH (2S)-2-(4-benzylphenoxy)-3-phenylpropanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris, pH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.10 Å R-free 0.290 |
| 3IA6 X-ray Crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a PPAR gamma/alpha dual agonist Deposited 2009-07-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：UNP residue 235-505
Chain B
235–505（271 aa）
Fragment：UNP residue 235-505
|
Not recorded | UNT (2S)-3-{4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propyl]phenyl}-2-(2H-1,2,3-triazol-2-yl)propanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；288 K；well solution consisting of 0.6 - 0.8 M tri-sodium citrate, 0.1 M imidazole pH 8 and 1 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 288K
|
Resolution 2.31 Å R-free 0.297 |
| 3IA6 X-ray Crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a PPAR gamma/alpha dual agonist Deposited 2009-07-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：UNP residue 235-505
Chain B
235–505（271 aa）
Fragment：UNP residue 235-505
|
Not recorded | UNT (2S)-3-{4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propyl]phenyl}-2-(2H-1,2,3-triazol-2-yl)propanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；288 K；well solution consisting of 0.6 - 0.8 M tri-sodium citrate, 0.1 M imidazole pH 8 and 1 mM TCEP, VAPOR DIFFUSION, HANGING DROP, temperature 288K
|
Resolution 2.31 Å R-free 0.297 |
| 3K8S Crystal Structure of PPARg in complex with T2384 Deposited 2009-10-14 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Fragment：UNP residues 234-505, Ligand binding domain
Chain B
234–505（272 aa）
Fragment：UNP residues 234-505, Ligand binding domain
|
Not recorded | Z27 2-chloro-N-{3-chloro-4-[(5-chloro-1,3-benzothiazol-2-yl)sulfanyl]phenyl}-4-(trifluoromethyl)benzenesulfonamide × 3 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.55 Å R-free 0.273 |
| 3K8S Crystal Structure of PPARg in complex with T2384 Deposited 2009-10-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
234–505（272 aa）
Fragment：UNP residues 234-505, Ligand binding domain
|
Not recorded | Z27 2-chloro-N-{3-chloro-4-[(5-chloro-1,3-benzothiazol-2-yl)sulfanyl]phenyl}-4-(trifluoromethyl)benzenesulfonamide × 1 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.55 Å R-free 0.273 |
| 3K8S Crystal Structure of PPARg in complex with T2384 Deposited 2009-10-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
234–505（272 aa）
Fragment：UNP residues 234-505, Ligand binding domain
|
Not recorded | Z27 2-chloro-N-{3-chloro-4-[(5-chloro-1,3-benzothiazol-2-yl)sulfanyl]phenyl}-4-(trifluoromethyl)benzenesulfonamide × 2 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.55 Å R-free 0.273 |
| 3KMG The X-ray Crystal Structure of PPAR-gamma in Complex with an Indole Derivative Modulator, GSK538, and an SRC-1 Peptide Deposited 2009-11-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Fragment：UNP residues 234-505
|
Not recorded | 538 4'-[(2,3-dimethyl-5-{[(1S)-1-phenylpropyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；Diffraction grade crystals grew in 7-14 days at 22C using 2uL vapor diffused hanging drops made with 1uL of the complex and 1uL of the well solution comprised of 14% PEG4K, 0.2M NaSCN and 0.1M Bis-tris pH 6.5., VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.10 Å R-free 0.230 |
| 3KMG The X-ray Crystal Structure of PPAR-gamma in Complex with an Indole Derivative Modulator, GSK538, and an SRC-1 Peptide Deposited 2009-11-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
234–505（272 aa）
Fragment：UNP residues 234-505
|
Not recorded | 538 4'-[(2,3-dimethyl-5-{[(1S)-1-phenylpropyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；295 K；Diffraction grade crystals grew in 7-14 days at 22C using 2uL vapor diffused hanging drops made with 1uL of the complex and 1uL of the well solution comprised of 14% PEG4K, 0.2M NaSCN and 0.1M Bis-tris pH 6.5., VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.10 Å R-free 0.230 |
| 3LMP Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Deposited 2010-01-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Fragment：UNP residues 234-505
|
Not recorded | CEK (9aS)-8-acetyl-1,7-dihydroxy-3-methoxy-9a-methyl-N-(1-naphthylmethyl)-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, NaSCN, vapor diffusion, temperature 295K, VAPOR DIFFUSION, HANGING DROP, pH 8.5
|
Resolution 1.90 Å R-free 0.242 |
| 3NOA Crystal structure of human PPAR-gamma ligand binding domain complex with a potency improved agonist Deposited 2010-06-25 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：lignad binding domain
Chain B
235–505（271 aa）
Fragment：lignad binding domain
|
Not recorded | 5BC (5-{3-[4-(biphenyl-4-ylcarbonyl)-2-propylphenoxy]propoxy}-1H-indol-1-yl)acetic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；291 K；27.5% PEG 3350, 16mM sodium citrate, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 1.98 Å R-free 0.275 |
| 3OSI Crystal structure of PPARgamma ligand binding domain in complex with tetrachloro-bisphenol A (TCBPA) Deposited 2010-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
224–504（281 aa）
Fragment：ligand binding domain
|
Not recorded | XDH 4,4'-propane-2,2-diylbis(2,6-dichlorophenol) × 1 PGO S-1,2-PROPANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1M tri-sodium citrate, 100 mM Hepes, 3% 1,2-propanediol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.70 Å R-free 0.253 |
| 3OSI Crystal structure of PPARgamma ligand binding domain in complex with tetrachloro-bisphenol A (TCBPA) Deposited 2010-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
224–504（281 aa）
Fragment：ligand binding domain
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1M tri-sodium citrate, 100 mM Hepes, 3% 1,2-propanediol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.70 Å R-free 0.253 |
| 3OSW Crystal structure of PPARgamma ligand binding domain in complex with tetrabromo-bisphenol A (TBBPA) Deposited 2010-09-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
224–504（281 aa）
Fragment：ligand binding domain
|
Not recorded | XDI 4,4'-propane-2,2-diylbis(2,6-dibromophenol) × 1 PGO S-1,2-PROPANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1M tri-sodium citrate, 100 mM Hepes, 3.5% 1,2-propanediol, 0.2 mM TBBPA, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.55 Å R-free 0.251 |
| 3OSW Crystal structure of PPARgamma ligand binding domain in complex with tetrabromo-bisphenol A (TBBPA) Deposited 2010-09-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
224–504（281 aa）
Fragment：ligand binding domain
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；1M tri-sodium citrate, 100 mM Hepes, 3.5% 1,2-propanediol, 0.2 mM TBBPA, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.55 Å R-free 0.251 |
| 3PBA Crystal structure of PPARgamma ligand binding domain in complex with monosulfate tetrabromo-bisphenol A (MonoTBBPA) Deposited 2010-10-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
224–505（282 aa）
Fragment：ligand binding domain
|
Not recorded | ZXG 2,6-dibromo-4-[2-(3,5-dibromo-4-hydroxyphenyl)propan-2-yl]phenyl hydrogen sulfate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；tri-sodium citrate, Hepes, 1,2-propanediol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å R-free 0.255 |
| 3PBA Crystal structure of PPARgamma ligand binding domain in complex with monosulfate tetrabromo-bisphenol A (MonoTBBPA) Deposited 2010-10-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
224–505（282 aa）
Fragment：ligand binding domain
|
Not recorded | PGO S-1,2-PROPANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；tri-sodium citrate, Hepes, 1,2-propanediol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.30 Å R-free 0.255 |
| 3PO9 Crystal structure of PPARgamma ligand binding domain in complex with tripropyltin Deposited 2010-11-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
224–505（282 aa）
Fragment：ligand binding domain
|
Not recorded | XPT 1-[chloro(dipropyl)-lambda~4~-sulfanyl]propane × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；1.2M tri-sodium citrate, 100mM Hepes, 3.5% 1,2-propanediol, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.35 Å R-free 0.269 |
| 3PO9 Crystal structure of PPARgamma ligand binding domain in complex with tripropyltin Deposited 2010-11-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
224–505（282 aa）
Fragment：ligand binding domain
|
Not recorded | XPT 1-[chloro(dipropyl)-lambda~4~-sulfanyl]propane × 1 PGO S-1,2-PROPANEDIOL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；1.2M tri-sodium citrate, 100mM Hepes, 3.5% 1,2-propanediol, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.35 Å R-free 0.269 |
| 3PRG LIGAND BINDING DOMAIN OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR Deposited 1998-08-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
202–475（274 aa）
Fragment：LIGAND BINDING DOMAIN
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 9.5；pH 9.50
|
Resolution 2.90 Å R-free 0.271 |
| 3QT0 Revealing a steroid receptor ligand as a unique PPARgamma agonist Deposited 2011-02-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：UNP residues 235-505
|
Not recorded | 486 11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；PEG, Tris-HCl, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å R-free 0.277 |
| 3R5N Crystal structure of PPARgammaLBD complexed with the agonist magnolol Deposited 2011-03-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
232–505（274 aa）
Fragment：ligand binding domain (UNP residues 232-505)
|
Not recorded | MLO 5,5'-di(prop-2-en-1-yl)biphenyl-2,2'-diol × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；4 M sodium formate, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å R-free 0.293 |
| 3R8A X-ray crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a compound with dual PPAR gamma agonism and Angiotensin II Type I receptor antagonism activity Deposited 2011-03-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
235–505（271 aa）
|
Not recorded | HIG 2-ethyl-5,7-dimethyl-3-{(1S)-5-[2-(1H-tetrazol-5-yl)phenyl]-2,3-dihydro-1H-inden-1-yl}-3H-imidazo[4,5-b]pyridine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；Apo crystals grown from Citrate/Imidazole, then soaked with 0.5 mM compound 2a, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.41 Å R-free 0.281 |
| 3R8A X-ray crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a compound with dual PPAR gamma agonism and Angiotensin II Type I receptor antagonism activity Deposited 2011-03-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
235–505（271 aa）
|
Not recorded | HIG 2-ethyl-5,7-dimethyl-3-{(1S)-5-[2-(1H-tetrazol-5-yl)phenyl]-2,3-dihydro-1H-inden-1-yl}-3H-imidazo[4,5-b]pyridine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；Apo crystals grown from Citrate/Imidazole, then soaked with 0.5 mM compound 2a, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.41 Å R-free 0.281 |
| 3R8I Crystal Structure of PPARgamma with an achiral ureidofibrate derivative (RT86) Deposited 2011-03-24 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：unp residues 223-505
Chain B
223–505（283 aa）
Fragment：unp residues 223-505
|
Not recorded | XCX 2-(4-{2-[1,3-benzoxazol-2-yl(heptyl)amino]ethyl}phenoxy)-2-methylpropanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；293 K；0.8 M NA Citrate, 0.15 M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.30 Å R-free 0.285 |
| 3R8I Crystal Structure of PPARgamma with an achiral ureidofibrate derivative (RT86) Deposited 2011-03-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
223–505（283 aa）
Fragment：unp residues 223-505
|
Not recorded | XCX 2-(4-{2-[1,3-benzoxazol-2-yl(heptyl)amino]ethyl}phenoxy)-2-methylpropanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；293 K；0.8 M NA Citrate, 0.15 M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.30 Å R-free 0.285 |
| 3R8I Crystal Structure of PPARgamma with an achiral ureidofibrate derivative (RT86) Deposited 2011-03-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
223–505（283 aa）
Fragment：unp residues 223-505
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；293 K；0.8 M NA Citrate, 0.15 M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.30 Å R-free 0.285 |
| 3S9S Ligand binding domain of PPARgamma complexed with a benzimidazole partial agonist Deposited 2011-06-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Fragment：LIGAND BINDING DOMAIN (RESIDUES 234-505)
|
Not recorded | M0T 1-(3,4-dichlorobenzyl)-2-methyl-N-[(1R)-1-phenylpropyl]-1H-benzimidazole-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；100MM HEPES, 1.4M SODIUM CITRATE, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.55 Å R-free 0.284 |
| 3SZ1 Human PPAR gamma ligand binding domain in complex with luteolin and myristic acid Deposited 2011-07-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
232–505（274 aa）
Fragment：Ligand binding domain
|
Not recorded | KNA nonanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；Sodium Citrate 0.90 M, HEPES 0.1 M, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.30 Å R-free 0.240 |
| 3SZ1 Human PPAR gamma ligand binding domain in complex with luteolin and myristic acid Deposited 2011-07-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
232–505（274 aa）
Fragment：Ligand binding domain
|
Not recorded | LU2 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one × 1 MYR MYRISTIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；Sodium Citrate 0.90 M, HEPES 0.1 M, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.30 Å R-free 0.240 |
| 3T03 Crystal structure of PPAR gamma ligand binding domain in complex with a novel partial agonist GQ-16 Deposited 2011-07-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: monomeric |
Chain A
234–505（272 aa）
Fragment：UNP residues 234-505
|
Not recorded | 3T0 (5Z)-5-(5-bromo-2-methoxybenzylidene)-3-(4-methylbenzyl)-1,3-thiazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0.2 M Ammonium acetate, 0.1 M Sodium citrate, pH 5.6, 30%(w/v) PEG 4000, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.10 Å R-free 0.247 |
| 3T03 Crystal structure of PPAR gamma ligand binding domain in complex with a novel partial agonist GQ-16 Deposited 2011-07-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: monomeric |
Chain B
234–505（272 aa）
Fragment：UNP residues 234-505
|
Not recorded | 3T0 (5Z)-5-(5-bromo-2-methoxybenzylidene)-3-(4-methylbenzyl)-1,3-thiazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；0.2 M Ammonium acetate, 0.1 M Sodium citrate, pH 5.6, 30%(w/v) PEG 4000, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.10 Å R-free 0.247 |
| 3TY0 Structure of PPARgamma ligand binding domain in complex with (R)-5-(3-((3-(6-methoxybenzo[d]isoxazol-3-yl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)phenyl)-5-methyloxazolidine-2,4-dione Deposited 2011-09-23 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Chain B
231–505（275 aa）
|
Not recorded | 082 (5R)-5-(3-{[3-(6-methoxy-1,2-benzoxazol-3-yl)-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl]methyl}phenyl)-5-methyl-1,3-oxazolidine-2,4-dione × 2 | X-RAY DIFFRACTION mmCIF provides none of the parsed conditions | Resolution 2.00 Å R-free 0.273 |
| 3U9Q Ligand binding domain of PPARgamma complexed with Decanoic Acid and PGC-1a peptide Deposited 2011-10-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
236–504（269 aa）
Fragment：Ligand Binding Domain, UNP residues 236-504
|
Not recorded | DKA DECANOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.2；298 K；0.2 M sodium acetate (pH 6.2), 20% PEG 3350, 15% glycerol and 1 mM concentration of the ligand., VAPOR DIFFUSION, temperature 298K
|
Resolution 1.52 Å R-free 0.222 |
| 3V9T Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Deposited 2011-12-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Fragment：ligand binding domain, UNP residues 234-505
|
Not recorded | 17L (9aS)-8-acetyl-N-[(3-ethoxynaphthalen-1-yl)methyl]-1,7-dihydroxy-3-methoxy-9a-methyl-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, sodium thiocyanate, Tris-hydrochloride, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 1.65 Å R-free 0.219 |
| 3V9V Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Deposited 2011-12-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Fragment：ligand binding domain, UNP residues 234-505
|
Not recorded | 21L methyl 3-{4-[({[(9aS)-8-acetyl-1,7-dihydroxy-3-methoxy-9a-methyl-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-yl]carbonyl}amino)methyl]naphthalen-2-yl}propanoate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, sodium thiocyanate, Tris-hydrochloride, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 1.60 Å R-free 0.244 |
| 3V9Y Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Deposited 2011-12-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Fragment：ligand binding domain, UNP residues 234-505
|
Not recorded | 24L 4-{4-[({[(9aS)-8-acetyl-1,7-dihydroxy-3-methoxy-9a-methyl-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-yl]carbonyl}amino)methyl]naphthalen-2-yl}butanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, sodium thiocyanate, Tris-hydrochloride, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.10 Å R-free 0.252 |
| 3VJH Human PPAR GAMMA ligand binding domain in complex with JKPL35 Deposited 2011-10-20 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：UNP RESIDUES 223-504
Chain B
223–504（282 aa）
Fragment：UNP RESIDUES 223-504
|
Not recorded | J35 (2S)-2-[4-methoxy-3-({[4-(trifluoromethyl)benzoyl]amino}methyl)benzyl]pentanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M Sodium citrate, 0.1M HEPES (pH7.5), VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.22 Å R-free 0.247 |
| 3VJI Human PPAR gamma ligand binding domain in complex with JKPL53 Deposited 2011-10-20 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：UNP RESIDUES 223-504
Chain B
223–504（282 aa）
Fragment：UNP RESIDUES 223-504
|
Not recorded | J53 (2S)-2-{4-butoxy-3-[({4-[(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]dec-1-yl]benzoyl}amino)methyl]benzyl}butanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.8M Sodium Citrate, 0.1M HEPES (pH7.5), VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.61 Å R-free 0.280 |
| 3VN2 Crystal Structure of PPARgamma complexed with Telmisartan Deposited 2011-12-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
225–505（281 aa）
Fragment：Ligand biding domain, UNP residues 225-505
|
Not recorded | TLS 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.1M TRIS-HCL, 0.8M SODIUM CITRATE TRIBASIC DIHYDRATE, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293.0K
|
Resolution 2.18 Å R-free 0.309 |
| 3VSO Human PPAR gamma ligand binding domain in complex with a gamma selective agonist mekt21 Deposited 2012-04-30 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：Ligand binding domain
Chain B
223–504（282 aa）
Fragment：Ligand binding domain
|
Not recorded | EK1 (2R)-2-benzyl-3-[4-propoxy-3-({[4-(pyrimidin-2-yl)benzoyl]amino}methyl)phenyl]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å R-free 0.257 |
| 3VSO Human PPAR gamma ligand binding domain in complex with a gamma selective agonist mekt21 Deposited 2012-04-30 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：Ligand binding domain
Chain B
223–504（282 aa）
Fragment：Ligand binding domain
|
Not recorded | EK1 (2R)-2-benzyl-3-[4-propoxy-3-({[4-(pyrimidin-2-yl)benzoyl]amino}methyl)phenyl]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å R-free 0.257 |
| 3VSP Human PPAR gamma ligand binding domain in complex with a gamma selective agonist mekt28 Deposited 2012-04-30 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：Ligand binding domain
Chain B
223–504（282 aa）
Fragment：Ligand binding domain
|
Not recorded | EK8 (2R)-2-benzyl-3-[3-({[4-(piperidin-1-yl)benzoyl]amino}methyl)-4-propoxyphenyl]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å R-free 0.274 |
| 3VSP Human PPAR gamma ligand binding domain in complex with a gamma selective agonist mekt28 Deposited 2012-04-30 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：Ligand binding domain
Chain B
223–504（282 aa）
Fragment：Ligand binding domain
|
Not recorded | EK8 (2R)-2-benzyl-3-[3-({[4-(piperidin-1-yl)benzoyl]amino}methyl)-4-propoxyphenyl]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å R-free 0.274 |
| 3WJ4 Crystal structure of PPARgamma ligand binding domain in complex with tributyltin Deposited 2013-10-04 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：UNP residues 235-505
Chain B
235–505（271 aa）
Fragment：UNP residues 235-505
|
Not recorded | TBY tributylstannanyl × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；100mM Tris-HCl pH 8.5, 160mM CH3COONH4, 19-23% PEG 4000, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.95 Å R-free 0.241 |
| 3WJ5 Crystal structure of PPARgamma ligand binding domain in complex with triphenyltin Deposited 2013-10-04 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：UNP residues 235-505
Chain B
235–505（271 aa）
Fragment：UNP residues 235-505
|
Not recorded | T9T triphenylstannanyl × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；277 K；100mM Tris-HCl pH 8.5, 160mM CH3COONH4, 19-23% PEG 4000, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.89 Å R-free 0.247 |
| 3WMH Human PPAR gamma ligand binding domain in complex with a gammma selective synthetic partial agonist MEKT75 Deposited 2013-11-19 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Fragment：Ligand binding domain, UNP residues 223-504
Chain B
223–504（282 aa）
Fragment：Ligand binding domain, UNP residues 223-504
|
Not recorded | JJA N-(phenylsulfonyl)-4-propoxy-3-({[4-(pyrimidin-2-yl)benzoyl]amino}methyl)benzamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.8M SODIUM CITRATE, 0.1M HEPES, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.10 Å R-free 0.258 |
| 3X1H hPPARgamma Ligand binding domain in complex with 5-oxo-tricosahexaenoic acid Deposited 2014-11-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
232–505（274 aa）
Fragment：ligand binding domain, UNP residues 232-505
|
Not recorded | 5OX (7E,11Z,14Z,17Z,20Z)-5-oxotricosa-7,11,14,17,20-pentaenoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；0.1M Tris-HCl PH 8, 0.7M sodium citrate, 1MM TCEP, 0.5MM EDTA, UNDER NITROGEN, temperature 293K, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.30 Å R-free 0.266 |
| 3X1H hPPARgamma Ligand binding domain in complex with 5-oxo-tricosahexaenoic acid Deposited 2014-11-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
232–505（274 aa）
Fragment：ligand binding domain, UNP residues 232-505
|
Not recorded | 5OX (7E,11Z,14Z,17Z,20Z)-5-oxotricosa-7,11,14,17,20-pentaenoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；293 K；0.1M Tris-HCl PH 8, 0.7M sodium citrate, 1MM TCEP, 0.5MM EDTA, UNDER NITROGEN, temperature 293K, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.30 Å R-free 0.266 |
| 3X1I hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic acid Deposited 2014-11-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
232–505（274 aa）
Fragment：ligand binding domain, UNP residues 232-505
|
Not recorded | 66B (8E,12Z,15Z,18Z,21Z)-6-oxotetracosa-8,12,15,18,21-pentaenoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；0.1M Tris-HCl PH 7.4, 0.7M sodium citrate, 1MM TCEP, 0.5MM EDTA, UNDER NITROGEN, temperature 293K, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.40 Å R-free 0.279 |
| 3X1I hPPARgamma Ligand binding domain in complex with 6-oxo-tetracosahexaenoic acid Deposited 2014-11-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
232–505（274 aa）
Fragment：ligand binding domain, UNP residues 232-505
|
Not recorded | 66B (8E,12Z,15Z,18Z,21Z)-6-oxotetracosa-8,12,15,18,21-pentaenoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；0.1M Tris-HCl PH 7.4, 0.7M sodium citrate, 1MM TCEP, 0.5MM EDTA, UNDER NITROGEN, temperature 293K, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.40 Å R-free 0.279 |
| 4A4V Ligand binding domain of human PPAR gamma in complex with amorfrutin 2 Deposited 2011-10-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
195–477（283 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 195-477
|
Not recorded | YFD AMORFRUTIN 2 × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；0.8 M TRI-SODIUM CITRATE, 0.1 M IMIDAZOLE, PH 8.0
|
Resolution 2.00 Å R-free 0.259 |
| 4A4V Ligand binding domain of human PPAR gamma in complex with amorfrutin 2 Deposited 2011-10-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
195–477（283 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 195-477
|
Not recorded | YFD AMORFRUTIN 2 × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；0.8 M TRI-SODIUM CITRATE, 0.1 M IMIDAZOLE, PH 8.0
|
Resolution 2.00 Å R-free 0.259 |
| 4A4W Ligand binding domain of human PPAR gamma in complex with amorfrutin B Deposited 2011-10-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
195–477（283 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 195-477
|
Not recorded | YFB AMORFRUTIN B × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；0.8 M TRI-SODIUM CITRATE 0.1 M IMIDAZOLE, PH 8.0
|
Resolution 2.00 Å R-free 0.234 |
| 4A4W Ligand binding domain of human PPAR gamma in complex with amorfrutin B Deposited 2011-10-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
195–477（283 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 195-477
|
Not recorded | YFB AMORFRUTIN B × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；0.8 M TRI-SODIUM CITRATE 0.1 M IMIDAZOLE, PH 8.0
|
Resolution 2.00 Å R-free 0.234 |
| 4CI5 Structural basis for GL479 a dual Peroxisome Proliferator-Activated Receptor gamma agonist Deposited 2013-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
206–477（272 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 206-477
|
Not recorded | Y1N 2-methyl-2-[4-[2-[4-[(E)-phenyldiazenyl]phenoxy]ethyl]phenoxy]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
0.8 M SODIUM CITRATE TRIBASIC DIHYDRATE, 0.1 M HEPES PH 8.0
|
Resolution 1.77 Å R-free 0.212 |
| 4CI5 Structural basis for GL479 a dual Peroxisome Proliferator-Activated Receptor gamma agonist Deposited 2013-12-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
206–477（272 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 206-477
|
Not recorded | Y1N 2-methyl-2-[4-[2-[4-[(E)-phenyldiazenyl]phenoxy]ethyl]phenoxy]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
0.8 M SODIUM CITRATE TRIBASIC DIHYDRATE, 0.1 M HEPES PH 8.0
|
Resolution 1.77 Å R-free 0.212 |
| 4E4K Crystal Structure of PPARgamma with the ligand JO21 Deposited 2012-03-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：Ligand binding domain (UNP residues 223-505)
Chain B
223–505（283 aa）
Fragment：Ligand binding domain (UNP residues 223-505)
|
Not recorded | RRG (2S)-3-phenyl-2-{[2'-(propan-2-yl)biphenyl-4-yl]oxy}propanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；293 K；0.8M NACITRATE, 0.15M TRIS, PH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293 KK
|
Resolution 2.50 Å R-free 0.335 |
| 4E4K Crystal Structure of PPARgamma with the ligand JO21 Deposited 2012-03-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：Ligand binding domain (UNP residues 223-505)
Chain B
223–505（283 aa）
Fragment：Ligand binding domain (UNP residues 223-505)
|
Not recorded | RRG (2S)-3-phenyl-2-{[2'-(propan-2-yl)biphenyl-4-yl]oxy}propanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8；293 K；0.8M NACITRATE, 0.15M TRIS, PH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293 KK
|
Resolution 2.50 Å R-free 0.335 |
| 4E4Q Crystal structure of PPARgamma with the ligand FS214 Deposited 2012-03-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：Ligand binding domain (UNP residues 223-505)
Chain B
223–505（283 aa）
Fragment：Ligand binding domain (UNP residues 223-505)
|
Not recorded | RRH (2R)-3-phenyl-2-{[2'-(propan-2-yl)biphenyl-4-yl]oxy}propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293 KK
|
Resolution 2.50 Å R-free 0.298 |
| 4E4Q Crystal structure of PPARgamma with the ligand FS214 Deposited 2012-03-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：Ligand binding domain (UNP residues 223-505)
Chain B
223–505（283 aa）
Fragment：Ligand binding domain (UNP residues 223-505)
|
Not recorded | RRH (2R)-3-phenyl-2-{[2'-(propan-2-yl)biphenyl-4-yl]oxy}propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293 KK
|
Resolution 2.50 Å R-free 0.298 |
| 4EM9 Human PPAR gamma in complex with nonanoic acids Deposited 2012-04-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-505
|
Not recorded | KNA nonanoic acid × 3 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1M tris-HCl, 0.9M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.10 Å R-free 0.235 |
| 4EM9 Human PPAR gamma in complex with nonanoic acids Deposited 2012-04-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-505
|
Not recorded | KNA nonanoic acid × 1 GOL GLYCEROL × 2 TCE 3,3',3''-phosphanetriyltripropanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1M tris-HCl, 0.9M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.10 Å R-free 0.235 |
| 4EM9 Human PPAR gamma in complex with nonanoic acids Deposited 2012-04-11 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-505
Chain B
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-505
|
Not recorded | KNA nonanoic acid × 8 GOL GLYCEROL × 6 TCE 3,3',3''-phosphanetriyltripropanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1M tris-HCl, 0.9M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.10 Å R-free 0.235 |
| 4EMA Human peroxisome proliferator-activated receptor gamma in complex with rosiglitazone Deposited 2012-04-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-505
|
Not recorded | BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1M tris-HCl, 0.9M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.54 Å R-free 0.225 |
| 4EMA Human peroxisome proliferator-activated receptor gamma in complex with rosiglitazone Deposited 2012-04-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-505
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1M tris-HCl, 0.9M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.54 Å R-free 0.225 |
| 4EMA Human peroxisome proliferator-activated receptor gamma in complex with rosiglitazone Deposited 2012-04-11 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-505
Chain B
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-505
|
Not recorded | BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；291 K；0.1M tris-HCl, 0.9M sodium citrate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.54 Å R-free 0.225 |
| 4F9M Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator Deposited 2012-05-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Fragment：Ligand binding domain, UNP residues 234-505
|
Not recorded | FCM (9aS)-8-acetyl-N-[(2-ethyl-4-fluoronaphthalen-1-yl)methyl]-1,7-dihydroxy-3-methoxy-9a-methyl-9-oxo-9,9a-dihydrodibenzo[b,d]furan-4-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, Sodium thiocyanate, Tris-HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 1.90 Å R-free 0.254 |
| 4FGY Identification of a unique PPAR ligand with an unexpected binding mode and antibetic activity Deposited 2012-06-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
235–504（270 aa）
Fragment：LIGAND BINDING DOMAIN, UNP RESIDUES 235-504
|
Not recorded | 0W3 (4R,6S,8S,12R,14R,16Z,18R,19R,20S,21S)-19,21-dihydroxy-22-{(2S,2'R,5S,5'S)-5'-[(1R)-1-hydroxyethyl]-2,5'-dimethyloctahydro-2,2'-bifuran-5-yl}-4,6,8,12,14,18,20-heptamethyl-9,11-dioxodocos-16-enoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；0.2 M sodium acetate, 5% ethylene glycol, 20% PEG 3350, pH 7.0, VAPOR DIFFUSION, HANGING DROP
|
Resolution 2.84 Å R-free 0.285 |
| 4HEE Crystal structure of PPARgamma in complex with compound 13 Deposited 2012-10-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain X
235–505（271 aa）
Fragment：peroxisome proliferator-activated receptor-gamma (UNP Residues 235-505)
|
Not recorded | 14R 5-benzyl-2-ethyl-3-{(1S)-5-[2-(1H-tetrazol-5-yl)phenyl]-2,3-dihydro-1H-inden-1-yl}-3,5-dihydro-4H-imidazo[4,5-c]pyridin-4-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；100mM PIPES, 200mM Sodium Thiocyanate, 16% PEG4000, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.50 Å R-free 0.258 |
| 4JAZ Crystal structure of the complex between PPARgamma LBD and trans-resveratrol Deposited 2013-02-19 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：UNP residues 223-505
Chain B
223–505（283 aa）
Fragment：UNP residues 223-505
|
Not recorded | STL RESVERATROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NA CITRATE, 0.15M TRIS, PH8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.85 Å R-free 0.264 |
| 4JL4 Crystal structure of the complex between PPARgamma LBD and the ligand LJ570 [(2S)-3-(biphenyl-4-yl)-2-(biphenyl-4-yloxy)propanoic acid] Deposited 2013-03-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：UNP residues 223-505
Chain B
223–505（283 aa）
Fragment：UNP residues 223-505
|
Not recorded | AXY (2S)-3-(biphenyl-4-yl)-2-(biphenyl-4-yloxy)propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8 M Na Citrate, 0.15 M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.50 Å R-free 0.287 |
| 4JL4 Crystal structure of the complex between PPARgamma LBD and the ligand LJ570 [(2S)-3-(biphenyl-4-yl)-2-(biphenyl-4-yloxy)propanoic acid] Deposited 2013-03-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：UNP residues 223-505
Chain B
223–505（283 aa）
Fragment：UNP residues 223-505
|
Not recorded | AXY (2S)-3-(biphenyl-4-yl)-2-(biphenyl-4-yloxy)propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8 M Na Citrate, 0.15 M Tris, pH 8.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.50 Å R-free 0.287 |
| 4L96 Structure of the complex between the F360L PPARgamma mutant and the ligand LT175 (space group I222) Deposited 2013-06-18 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN (UNP RESIDUES 235-505)
|
Mutation：F360L | LRG (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.9；293 K；0.35M Na-phosphate, 0.65 M K-phosphate., pH 6.9, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.38 Å R-free 0.226 |
| 4L98 Crystal structure of the complex of F360L PPARgamma mutant with the ligand LT175 Deposited 2013-06-18 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN (UNP RESIDUES 235-505)
Chain B
235–505（271 aa）
Fragment：LIGAND BINDING DOMAIN (UNP RESIDUES 235-505)
|
Mutation：F360L Mutation：F360L | LRG (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；3.3 M Sodium Formate, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.28 Å R-free 0.258 |
| 4O8F Crystal Structure of the complex between PPARgamma mutant R357A and rosiglitazone Deposited 2013-12-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：Ligand Binding Domain
Chain B
223–505（283 aa）
Fragment：Ligand Binding Domain
|
Mutation：R357A Mutation：R357A | BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；MORPHEUS A5: 10% w/v PEG 20 000, 20% v/v PEG MME 550, 0.1 M MOPS/HEPES-Na, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.60 Å R-free 0.297 |
| 4O8F Crystal Structure of the complex between PPARgamma mutant R357A and rosiglitazone Deposited 2013-12-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
223–505（283 aa）
Fragment：Ligand Binding Domain
|
Mutation：R357A | BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；MORPHEUS A5: 10% w/v PEG 20 000, 20% v/v PEG MME 550, 0.1 M MOPS/HEPES-Na, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.60 Å R-free 0.297 |
| 4O8F Crystal Structure of the complex between PPARgamma mutant R357A and rosiglitazone Deposited 2013-12-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
223–505（283 aa）
Fragment：Ligand Binding Domain
|
Mutation：R357A | BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；MORPHEUS A5: 10% w/v PEG 20 000, 20% v/v PEG MME 550, 0.1 M MOPS/HEPES-Na, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.60 Å R-free 0.297 |
| 4OJ4 Crystal structure of V290M PPARgamma mutant in complex with diclofenac Deposited 2014-01-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
232–505（274 aa）
Fragment：Ligand binding domain (UNP residues 232-505)
|
Mutation：V290M | DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 2 CA CALCIUM ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；291 K；PEG 4000 30%, CaCl2 200 mM, HEPES 100 mM, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 291K
|
Resolution 2.30 Å R-free 0.284 |
| 4PRG 0072 PARTIAL AGONIST PPAR GAMMA COCRYSTAL Deposited 1999-05-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
205–474（270 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 207-476
Chain B
205–474（270 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 207-476
Chain C
205–474（270 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 207-476
Chain D
205–474（270 aa）
Fragment：LIGAND BINDING DOMAIN, RESIDUES 207-476
|
Not recorded | 072 (+/-)(2S,5S)-3-(4-(4-CARBOXYPHENYL)BUTYL)-2-HEPTYL-4-OXO-5-THIAZOLIDINE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 2.90 Å R-free 0.283 |
| 4PVU Crystal structure of the complex between PPARgamma-LBD and the R enantiomer of Mbx-102 (Metaglidasen) Deposited 2014-03-18 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：Ligand Binding Domain, UNP RESIDUES 223-505
Chain B
223–505（283 aa）
Fragment：Ligand Binding Domain, UNP RESIDUES 223-505
|
Not recorded | MGZ (2R)-(4-chlorophenyl)[3-(trifluoromethyl)phenoxy]ethanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M Sodium Citrate, pH 8, 0.15M Tris, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.60 Å R-free 0.251 |
| 4PWL Crystal structure of the complex between PPARgamma-LBD and the S enantiomer of Mbx-102 (Metaglidasen) Deposited 2014-03-20 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：Ligand Binding Domain, UNP RESIDUES 223-505
Chain B
223–505（283 aa）
Fragment：Ligand Binding Domain, UNP RESIDUES 223-505
|
Not recorded | MSZ (2S)-(4-chlorophenyl)[3-(trifluoromethyl)phenoxy]ethanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M Sodium Citrate, pH 8, 0.15M Tris, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.60 Å R-free 0.308 |
| 4R06 Crystal Structure of SR2067 bound to PPARgamma Deposited 2014-07-30 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
233–505（273 aa）
Fragment：UNP residues 233-505
Chain B
233–505（273 aa）
Fragment：UNP residues 233-505
|
Not recorded | 3E7 1-(naphthalen-1-ylsulfonyl)-N-[(1S)-1-phenylpropyl]-1H-indole-5-carboxamide × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；289 K；Protein ligand complex at 10mg/mL in 20mM Tris 8.0, 10mM NaCl, 1mM TCEP mixed with equal volume of well solution of 2M ammonium sulfate, VAPOR DIFFUSION, HANGING DROP, temperature 289K
|
Resolution 2.22 Å R-free 0.240 |
| 4R2U Crystal Structure of PPARgamma in complex with SR1664 Deposited 2014-08-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Fragment：UNP residues 231-505
Chain D
231–505（275 aa）
Fragment：UNP residues 231-505
|
Not recorded | 3JX 4'-[(2,3-dimethyl-5-{[(1S)-1-(4-nitrophenyl)ethyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；295 K；1uL protein-ligand complex solution (10mg/mL) was mixed with 1uL well solution (2M ammonium sulfate and 0.1M Tris 8.0), VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.30 Å R-free 0.248 |
| 4R2U Crystal Structure of PPARgamma in complex with SR1664 Deposited 2014-08-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Fragment：UNP residues 231-505
Chain D
231–505（275 aa）
Fragment：UNP residues 231-505
|
Not recorded | 3JX 4'-[(2,3-dimethyl-5-{[(1S)-1-(4-nitrophenyl)ethyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；295 K；1uL protein-ligand complex solution (10mg/mL) was mixed with 1uL well solution (2M ammonium sulfate and 0.1M Tris 8.0), VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.30 Å R-free 0.248 |
| 4R6S Crystal structure of PPARgammma in complex with SR1663 Deposited 2014-08-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Fragment：UNP residues 231-505
Chain B
231–505（275 aa）
Fragment：UNP residues 231-505
|
Mutation：T447F Mutation：T447F | 3K2 4'-[(2,3-dimethyl-5-{[(1R)-1-(4-nitrophenyl)ethyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；1.4M sodium citrate, 0.125M Tris 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.30 Å R-free 0.233 |
| 4R6S Crystal structure of PPARgammma in complex with SR1663 Deposited 2014-08-26 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Fragment：UNP residues 231-505
Chain B
231–505（275 aa）
Fragment：UNP residues 231-505
|
Mutation：T447F Mutation：T447F | 3K2 4'-[(2,3-dimethyl-5-{[(1R)-1-(4-nitrophenyl)ethyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；298 K；1.4M sodium citrate, 0.125M Tris 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.30 Å R-free 0.233 |
| 4XLD Crystal structure of the human PPARg-LBD/rosiglitazone complex obtained by dry co-crystallization and in situ diffraction Deposited 2015-01-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
203–477（275 aa）
Fragment：UNP residues 203-477
|
Not recorded | FMT FORMIC ACID × 1 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；291 K；3-4 M Sodium Formate
|
Resolution 2.45 Å R-free 0.222 |
| 4XTA MECHANISMS OF PPARgamma ACTIVATION BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS Deposited 2015-01-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
232–505（274 aa）
Fragment：UNP residues 232-505
|
Not recorded | DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；1 M sodium citrate, 0.1 M HEPES pH 7.5, and 10 mM MgCl2
|
Resolution 2.50 Å R-free 0.274 |
| 4XTA MECHANISMS OF PPARgamma ACTIVATION BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS Deposited 2015-01-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
232–505（274 aa）
Fragment：UNP residues 232-505
|
Not recorded | DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；1 M sodium citrate, 0.1 M HEPES pH 7.5, and 10 mM MgCl2
|
Resolution 2.50 Å R-free 0.274 |
| 4XTA MECHANISMS OF PPARgamma ACTIVATION BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS Deposited 2015-01-23 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
232–505（274 aa）
Fragment：UNP residues 232-505
Chain B
232–505（274 aa）
Fragment：UNP residues 232-505
|
Not recorded | DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；1 M sodium citrate, 0.1 M HEPES pH 7.5, and 10 mM MgCl2
|
Resolution 2.50 Å R-free 0.274 |
| 4XUH PPARgamma ligand binding domain in complex with sulindac sulfide Deposited 2015-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
232–505（274 aa）
Fragment：UNP residues 232-505
|
Not recorded | SFI 2-[(3Z)-6-fluoranyl-2-methyl-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]ethanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；25% (w/v) PEG 6000 and 0.1 M Tris-HCl pH 8.5.
|
Resolution 2.22 Å R-free 0.230 |
| 4XUH PPARgamma ligand binding domain in complex with sulindac sulfide Deposited 2015-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
232–505（274 aa）
Fragment：UNP residues 232-505
|
Not recorded | SFI 2-[(3Z)-6-fluoranyl-2-methyl-3-[(4-methylsulfanylphenyl)methylidene]inden-1-yl]ethanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；25% (w/v) PEG 6000 and 0.1 M Tris-HCl pH 8.5.
|
Resolution 2.22 Å R-free 0.230 |
| 4XUM PPARgamma ligand binding domain in complex with indomethacin Deposited 2015-01-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
232–505（274 aa）
|
Not recorded | IMN INDOMETHACIN × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.95 M sodium citrate and 0.1 M HEPES pH 8.0
|
Resolution 2.40 Å R-free 0.240 |
| 4XUM PPARgamma ligand binding domain in complex with indomethacin Deposited 2015-01-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
232–505（274 aa）
|
Not recorded | IMN INDOMETHACIN × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.95 M sodium citrate and 0.1 M HEPES pH 8.0
|
Resolution 2.40 Å R-free 0.240 |
| 4Y29 Identification of a novel PPARg ligand that regulates metabolism Deposited 2015-02-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
236–504（269 aa）
Fragment：UNP residues 236-504
|
Not recorded | CTI 1,2-dimethoxy-12-methyl[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293.15 K；0.2 M Sodium thiocyanate, 20% w/v PEG 3350
|
Resolution 1.98 Å R-free 0.219 |
| 5AZV Crystal structure of hPPARgamma ligand binding domain complexed with 17-oxoDHA Deposited 2015-10-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
232–505（274 aa）
Fragment：UNP residues 203-505
|
Not recorded | 4M5 (4~{Z},7~{Z},10~{Z},13~{Z},19~{Z})-17-oxidanylidenedocosa-4,7,10,13,19-pentaenoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；0.1 M Tris-HCl, 0.825 M sodium citrate
|
Resolution 2.70 Å R-free 0.307 |
| 5AZV Crystal structure of hPPARgamma ligand binding domain complexed with 17-oxoDHA Deposited 2015-10-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
232–505（274 aa）
Fragment：UNP residues 203-505
|
Not recorded | 4M5 (4~{Z},7~{Z},10~{Z},13~{Z},19~{Z})-17-oxidanylidenedocosa-4,7,10,13,19-pentaenoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；0.1 M Tris-HCl, 0.825 M sodium citrate
|
Resolution 2.70 Å R-free 0.307 |
| 5DSH Human PPARgamma ligand binding dmain complexed with SB1406 in a covalent bonded form Deposited 2015-09-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：UNP RESIDUES 223-505
|
Not recorded | 6BH N-[3-(benzyloxy)phenyl]-3-nitrobenzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；297 K；2.2M sodium malonate pH 7.0
|
Resolution 2.95 Å R-free 0.257 |
| 5DV3 Human PPARgamma ligand binding dmain complexed with SB1405 in a covalent bonded form Deposited 2015-09-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：UNP RESIDUES 223-505
|
Not recorded | B05 N-[2-(benzyloxy)phenyl]-3-nitrobenzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；297 K；2.2M sodium malonate pH 7.0
|
Resolution 2.75 Å R-free 0.230 |
| 5DV6 Human PPARgamma ligand binding dmain complexed with SB1404 in a covalent bonded form Deposited 2015-09-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：UNP RESIDUES 223-505
|
Not recorded | B4H N-methylidene-3-nitrobenzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；297 K；2.2M sodium malonate pH 7.0
|
Resolution 2.80 Å R-free 0.244 |
| 5DV8 Human PPARgamma ligand binding dmain complexed with SB1451 in a covalent bonded form Deposited 2015-09-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：UNP RESIDUES 223-505
|
Not recorded | T51 N-[2-({2-[({4-[(4-methylpiperazin-1-yl)methyl]benzoyl}amino)methyl]benzyl}oxy)phenyl]-3-nitrobenzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；297 K；0.19M sodium acetate trihydrate, 0.1M sodium cacodylate pH 6.5, 26% PEG 8000
|
Resolution 2.75 Å R-free 0.243 |
| 5DVC Human PPARgamma ligand binding dmain complexed with SB1453 in a covalent bonded form Deposited 2015-09-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：UNP RESIDUES 223-505
|
Not recorded | T53 N-[2-({3-[({4-[(4-methylpiperazin-1-yl)methyl]benzoyl}amino)methyl]benzyl}oxy)phenyl]-3-nitrobenzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；297 K；2.2 M sodium malonate pH 7.0
|
Resolution 2.30 Å R-free 0.241 |
| 5DWL Human PPARgamma ligand binding dmain in complex with SR1664 Deposited 2015-09-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：UNP RESIDUES 223-505
|
Not recorded | 3JX 4'-[(2,3-dimethyl-5-{[(1S)-1-(4-nitrophenyl)ethyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；297 K；2.2 M sodium malonate pH7.0
|
Resolution 2.20 Å R-free 0.238 |
| 5F9B X-ray crystal structure of PPARgamma in the complex with caulophyllogenin Deposited 2015-12-09 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
195–477（283 aa）
Fragment：UNP residues 195-477
Chain B
195–477（283 aa）
Fragment：UNP residues 195-477
|
Not recorded | 5VN Caulophyllogenin × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NA CITRATE, 0.15M TRIS, PH8.0
|
Resolution 2.25 Å R-free 0.281 |
| 5GTN Human PPARgamma ligand binding dmain complexed with R35 Deposited 2016-08-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：UNP RESIDUES 223-505
|
Not recorded | Q35 2-[4-[5-[(1~{R})-1-[(3,5-dimethoxyphenyl)carbamoyl-(phenylmethyl)carbamoyl]oxypropyl]-1,2-oxazol-3-yl]phenoxy]-2-methyl-propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；57.5% (v/v) Tacsimate pH7.0
|
Resolution 1.85 Å R-free 0.232 |
| 5GTO Human PPARgamma ligand binding dmain complexed with S35 Deposited 2016-08-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：UNP RESIDUES 1-283
|
Not recorded | T35 2-[4-[5-[(1~{S})-1-[(3,5-dimethoxyphenyl)carbamoyl-(phenylmethyl)carbamoyl]oxypropyl]-1,2-oxazol-3-yl]phenoxy]-2-methyl-propanoic acid × 1 MYR MYRISTIC ACID × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；2.2 M sodium malonate (pH 7.0)
|
Resolution 2.10 Å R-free 0.242 |
| 5GTP The agonist-free structure of human PPARgamma ligand binding domain in the presence of the SRC-1 coactivator peptide Deposited 2016-08-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：UNP RESIDUES 223-505
|
Not recorded | MYR MYRISTIC ACID × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；2.2 M sodium malonate (pH 7.0)
|
Resolution 2.35 Å R-free 0.258 |
| 5HZC Crystal structure of the complex PPARgamma/AL26-29 Deposited 2016-02-02 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Chain B
223–505（283 aa）
|
Not recorded | 65W 2-methyl-2-[4-(naphthalen-1-yl)phenoxy]propanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；291 K；Sodium citrate 0.8 M, Tris base 0.15 M
|
Resolution 2.00 Å R-free 0.270 |
| 5JI0 PPARgamma-RXRalpha(S427F) heterodimer in complex with SRC-1, rosiglitazone, and 9-cis-retanoic acid Deposited 2016-04-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain D
234–505（272 aa）
|
Not recorded | 9CR (9cis)-retinoic acid × 1 BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；296 K；Crystals grew in the dark at room temperature from 0.5 + 0.5 uL sitting drops equilibrated over a reservoir containing 20-24% PEG3350 and 0.02M Na Citrate
|
Resolution 1.98 Å R-free 0.246 |
| 5JI0 PPARgamma-RXRalpha(S427F) heterodimer in complex with SRC-1, rosiglitazone, and 9-cis-retanoic acid Deposited 2016-04-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
234–505（272 aa）
|
Not recorded | BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；296 K；Crystals grew in the dark at room temperature from 0.5 + 0.5 uL sitting drops equilibrated over a reservoir containing 20-24% PEG3350 and 0.02M Na Citrate
|
Resolution 1.98 Å R-free 0.246 |
| 5LSG PPARgamma complex with the betulinic acid Deposited 2016-08-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
223–505（283 aa）
Fragment：UNP residues 223-505
|
Not recorded | QZQ Betulinic Acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；290 K；reservoir: 0.8M NACITRATE, 0.15M TRIS, PH8.0.
The crystals were soaked for one week in a storage solution (1.2 M Na Citrate, 0.15M Tris, pH 8.0) containing the ligand BA (0.5 mM).
|
Resolution 2.00 Å R-free 0.264 |
| 5LSG PPARgamma complex with the betulinic acid Deposited 2016-08-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
223–505（283 aa）
Fragment：UNP residues 223-505
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；290 K；reservoir: 0.8M NACITRATE, 0.15M TRIS, PH8.0.
The crystals were soaked for one week in a storage solution (1.2 M Na Citrate, 0.15M Tris, pH 8.0) containing the ligand BA (0.5 mM).
|
Resolution 2.00 Å R-free 0.264 |
| 5TTO X-ray crystal structure of PPARgamma in complex with SR1643 Deposited 2016-11-04 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
233–505（273 aa）
Fragment：residues 233-505
Chain B
233–505（273 aa）
Fragment：residues 233-505
|
Not recorded | 7KK 4-bromo-N-{3,5-dichloro-4-[(quinolin-3-yl)oxy]phenyl}-2,5-difluorobenzene-1-sulfonamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；289 K；2M ammonium sulfate
|
Resolution 2.25 Å R-free 0.256 |
| 5TWO Peroxisome proliferator-activated receptor gamma ligand binding domain in complex with a novel selectively PPAR gamma-modulating ligand VSP-51 Deposited 2016-11-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Fragment：lignad binding domain (UNP residues 234-505)
|
Not recorded | 7MV N-benzyl-1-[(4-chloro-3-fluorophenyl)methyl]-1H-indole-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.5；293 K；0.1 M of tri-sodium citrate (pH 5.5), 20% w/v PEG 3350
|
Resolution 1.93 Å R-free 0.236 |
| 5U5L X-ray Crystal Structure of the PPARgamma Ligand Binding Domain in Complex with Rivoglitazone Deposited 2016-12-06 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
233–505（273 aa）
Fragment：residues 233-505
Chain B
233–505（273 aa）
Fragment：residues 233-505
|
Not recorded | 7VA (5S)-5-({4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl)methoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；289 K；1M Na Citrate
|
Resolution 2.55 Å R-free 0.238 |
| 5UGM Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Edaglitazone Deposited 2017-01-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
235–505（271 aa）
Fragment：UNP residues 235-505
|
Not recorded | 8A7 (5R)-5-({4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}methyl)-1,3-thiazolidine-2,4-dione × 2 KNA nonanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, PH 7.6
|
Resolution 2.10 Å R-free 0.216 |
| 5UGM Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Edaglitazone Deposited 2017-01-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
235–505（271 aa）
Fragment：UNP residues 235-505
|
Not recorded | 8A7 (5R)-5-({4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}methyl)-1,3-thiazolidine-2,4-dione × 2 KNA nonanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, PH 7.6
|
Resolution 2.10 Å R-free 0.216 |
| 5WQX Covalent bond formation of synthetic ligand with hPPARg-LBD Deposited 2016-11-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
232–505（274 aa）
Fragment：ligand binding domain, UNP residues 232-505
Chain B
232–505（274 aa）
Fragment：ligand binding domain, UNP residues 232-505
|
Not recorded | T65 2-[E-(E-2-oxidanylidenehexadec-5-enylidene)amino]ethanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；0.1M Tris-HCl PH 7.4, 0.8M sodium citrate
|
Resolution 2.29 Å R-free 0.277 |
| 5WR0 Huisgen cycloaddition for PPARg-LBD labeling by soaking method Deposited 2016-11-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
232–505（274 aa）
Fragment：ligand binding domain, UNP residues 232-505
Chain B
232–505（274 aa）
Fragment：ligand binding domain, UNP residues 232-505
|
Not recorded | 8Y0 (E)-N-[(3E)-2-oxo-16-(8-{6-[(trifluoroacetyl)amino]hexanoyl}-8,9-dihydro-1H-dibenzo[b,f][1,2,3]triazolo[4,5-d]azocin-1-yl)hexadec-3-en-1-ylidene]glycine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；0.1M Tris-HCl PH 7.4, 0.8M sodium citrate
|
Resolution 2.85 Å R-free 0.300 |
| 5WR1 Covalent bond formation of bifunctional ligand with hPPARg-LBD Deposited 2016-11-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
232–505（274 aa）
Fragment：ligand binding domain, UNP residues 232-505
Chain B
232–505（274 aa）
Fragment：ligand binding domain, UNP residues 232-505
|
Not recorded | 8XO 2-[E-(E-16-azido-2-oxidanylidene-hexadec-3-enylidene)amino]ethanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；0.1M Tris-HCl PH 7.4, 0.8M sodium citrate
|
Resolution 2.34 Å R-free 0.259 |
| 5Y2O Structure of PPARgamma ligand binding domain-pioglitazone complex Deposited 2017-07-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：UNP residues 235-505
Chain B
235–505（271 aa）
Fragment：UNP residues 235-505
|
Not recorded | 8N6 (5S)-5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；297 K；0.1M HEPES NaOH pH 7.5, 17.5% PEG 8000, 10% EG
|
Resolution 1.80 Å R-free 0.232 |
| 5Y2T Structure of PPARgamma ligand binding domain - lobeglitazone complex Deposited 2017-07-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Fragment：UNP residues 235-505
Chain B
235–505（271 aa）
Fragment：UNP residues 235-505
|
Not recorded | 8LX (5S)-5-[[4-[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methyl-amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；297 K；0.1M HEPES NaOH pH7.5, 17.5% PEG 8000, 10% DMSO
|
Resolution 1.70 Å R-free 0.224 |
| 5YCN Human PPARgamma ligand binding domain complexed with Lobeglitazone Deposited 2017-09-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：UNP RESIDUES 223-505
|
Not recorded | 8LX (5S)-5-[[4-[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methyl-amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；296 K；1.6 M sodium citrate tribasic dihydrate (pH 6.5)
|
Resolution 2.15 Å R-free 0.228 |
| 5YCP Human PPARgamma ligand binding domain complexed with Rosiglitazone Deposited 2017-09-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：UNP RESIDUES 223-505
|
Not recorded | BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；2.2 M sodium malonate (pH 7.0)
|
Resolution 2.00 Å R-free 0.233 |
| 5Z5S Crystal structure of the PPARgamma-LBD complexed with compound 13ab Deposited 2018-01-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
|
Not recorded | RTE 3-{[6-(4-chloro-3-fluorophenoxy)-1-methyl-1H-benzimidazol-2-yl]methoxy}benzoic acid × 1 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, NaSCN, Tris-HCl
|
Resolution 1.80 Å R-free 0.229 |
| 5Z6S Crystal structure of the PPARgamma-LBD complexed with compound DS-6930 Deposited 2018-01-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
|
Not recorded | RTF 3-[[6-(3,5-dimethylpyridin-2-yl)oxy-1-methyl-benzimidazol-2-yl]methoxy]benzoic acid × 1 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, sodium thiocyanate, Tris-hydrochloride
|
Resolution 1.80 Å R-free 0.226 |
| 6AD9 Crystal Structure of PPARgamma Ligand Binding Domain in complex with dibenzooxepine derivative compound-9 Deposited 2018-07-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Fragment：ligand binding domain
|
Not recorded | KK4 3-[(1E)-1-{8-[(4-methyl-2-propyl-1H-benzimidazol-1-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}ethyl]-1,2,4-oxadiazol-5(4H)-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8.5；293 K；0.5M LiCl, 0.1M Tris-HCl pH 8.5, 28% PEG 6000
|
Resolution 2.20 Å R-free 0.240 |
| 6AN1 Crystal structure of the complex between PPARgamma LBD and the ligand AM-879 Deposited 2017-08-11 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
196–477（282 aa）
Chain B
196–477（282 aa）
|
Not recorded | BKY 4-({2-[(1,3-dioxo-1,3-dihydro-2H-inden-2-ylidene)methyl]phenoxy}methyl)benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.9M tri-sodium citrate, 100mM Hepes, 3.5% 1,2-propanediol, pH 7.0
|
Resolution 2.69 Å R-free 0.275 |
| 6AUG Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with SR16832 Deposited 2017-08-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
Fragment：UNP residues 231-505
|
Not recorded | BXG 2-chloro-N-(6-methoxyquinolin-4-yl)-5-nitrobenzamide × 1 KNA nonanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 2.73 Å R-free 0.281 |
| 6AUG Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with SR16832 Deposited 2017-08-31 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
Fragment：UNP residues 231-505
|
Not recorded | BXG 2-chloro-N-(6-methoxyquinolin-4-yl)-5-nitrobenzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 2.73 Å R-free 0.281 |
| 6AUG Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with SR16832 Deposited 2017-08-31 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Fragment：UNP residues 231-505
Chain B
231–505（275 aa）
Fragment：UNP residues 231-505
|
Not recorded | BXG 2-chloro-N-(6-methoxyquinolin-4-yl)-5-nitrobenzamide × 2 KNA nonanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 2.73 Å R-free 0.281 |
| 6AVI Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Nonanoic acid Deposited 2017-09-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
Fragment：UNP residues 231-505
|
Not recorded | GW9 2-chloro-5-nitro-N-phenylbenzamide × 1 KNA nonanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM TRIS, pH 7.6
|
Resolution 2.29 Å R-free 0.314 |
| 6AVI Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Nonanoic acid Deposited 2017-09-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
Fragment：UNP residues 231-505
|
Not recorded | GW9 2-chloro-5-nitro-N-phenylbenzamide × 1 KNA nonanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM TRIS, pH 7.6
|
Resolution 2.29 Å R-free 0.314 |
| 6C1I Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with T0070907 Deposited 2018-01-04 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–504（274 aa）
Chain B
231–504（274 aa）
|
Not recorded | EEY 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide × 2 KNA nonanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.5；298 K；0.1 M MOPS, pH 6.5, 0.8 M sodium citrate
|
Resolution 2.26 Å R-free 0.283 |
| 6C5Q PPARg LBD bound to SR10171 Deposited 2018-01-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
235–505（271 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | EKS 2-{3-[(5-{[(1S)-1-(4-tert-butylphenyl)ethyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]phenoxy}-2-methylpropanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；4M ammonium acetate, O.1M bis-tris propane 7.0
|
Resolution 2.40 Å R-free 0.277 |
| 6C5T PPARg LBD bound to SR11023 Deposited 2018-01-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
235–505（271 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | EKP 2-{4-[(5-{[(1R)-1-(3-cyclopropylphenyl)ethyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]phenyl}-2-methylpropanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；289 K；20% PEG 3350 + 0.2M ammonium citrate 7.0
|
Resolution 2.75 Å R-free 0.286 |
| 6D3E PPARg LBD in Complex with SR1988 Deposited 2018-04-15 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–504（270 aa）
Fragment：Ligand Binding Domain
Chain B
235–504（270 aa）
Fragment：Ligand Binding Domain
|
Not recorded | FT7 1-[(2,4-difluorophenyl)methyl]-2,3-dimethyl-N-[(1R)-1-phenylpropyl]-1H-indole-5-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；289 K；1.2M sodium citrate
|
Resolution 2.40 Å R-free 0.264 |
| 6D8X PPAR gamma LBD complexed with the agonist GW1929 Deposited 2018-04-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 FLC CITRATE ANION × 1 NA SODIUM ION × 3 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；200mM tri-Lithium Citrate
20% (w/v) PEG 3350
|
Resolution 1.90 Å R-free 0.245 |
| 6D94 Crystal structure of PPAR gamma in complex with Mediator of RNA polymerase II transcription subunit 1 Deposited 2018-04-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；277 K；100mM HEPES
25% (w/v) PEG 2000 MME
|
Resolution 1.90 Å R-free 0.258 |
| 6DBH Crystal structure of PPAR gamma in complex with NMP422 Deposited 2018-05-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | G3S 4-{2-[(2,3-dioxo-1-pentyl-2,3-dihydro-1H-indol-5-yl)sulfanyl]ethyl}benzoic acid × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；1.0M Sodium citrate
|
Resolution 2.60 Å R-free 0.262 |
| 6DBH Crystal structure of PPAR gamma in complex with NMP422 Deposited 2018-05-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
|
Not recorded | G3S 4-{2-[(2,3-dioxo-1-pentyl-2,3-dihydro-1H-indol-5-yl)sulfanyl]ethyl}benzoic acid × 1 CL CHLORIDE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；1.0M Sodium citrate
|
Resolution 2.60 Å R-free 0.262 |
| 6DCU Crystal structure of PPAR gamma co-crystallized with nTZDpa Deposited 2018-05-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
203–477（275 aa）
|
Not recorded | NZA 5-CHLORO-1-(4-CHLOROBENZYL)-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；0.2 M Potassium thiocyanate
20%(w/v) PEG 3350
|
Resolution 2.95 Å R-free 0.303 |
| 6DCU Crystal structure of PPAR gamma co-crystallized with nTZDpa Deposited 2018-05-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
203–477（275 aa）
|
Not recorded | NZA 5-CHLORO-1-(4-CHLOROBENZYL)-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；0.2 M Potassium thiocyanate
20%(w/v) PEG 3350
|
Resolution 2.95 Å R-free 0.303 |
| 6DGL Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Darglitazone Deposited 2018-05-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | GEV (5Z)-5-({4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl}methylidene)-1,3-thiazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 1.95 Å R-free 0.269 |
| 6DGL Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Darglitazone Deposited 2018-05-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
|
Not recorded | GEV (5Z)-5-({4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl}methylidene)-1,3-thiazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 1.95 Å R-free 0.269 |
| 6DGO Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Troglitazone Deposited 2018-05-17 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Chain B
231–505（275 aa）
|
Not recorded | GD4 (5S)-5-[(4-{[(2R)-6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-yl]methoxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 3.10 Å R-free 0.276 |
| 6DGP Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with TRAP220 Coactivator Peptide Deposited 2018-05-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.1M Magnesium acetate,
0.1M Sodium cacodylate, pH 6.5
15% w/v, PEG 6000
|
Resolution 3.10 Å R-free 0.294 |
| 6DGP Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with TRAP220 Coactivator Peptide Deposited 2018-05-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.1M Magnesium acetate,
0.1M Sodium cacodylate, pH 6.5
15% w/v, PEG 6000
|
Resolution 3.10 Å R-free 0.294 |
| 6DGQ Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with CAY10506 Deposited 2018-05-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | GBV N-(2-{4-[(2,4-dioxo-3,4-dihydro-2H-1lambda~4~,3-thiazol-5-yl)methyl]phenoxy}ethyl)-5-[(3R)-1,2-dithiolan-3-yl]pentanamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.8M SODIUM CITRATE, 100mM Tris, pH 7.6
|
Resolution 2.45 Å R-free 0.247 |
| 6DGQ Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with CAY10506 Deposited 2018-05-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.8M SODIUM CITRATE, 100mM Tris, pH 7.6
|
Resolution 2.45 Å R-free 0.247 |
| 6DGR Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with CAY10638 Deposited 2018-05-18 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Chain B
231–505（275 aa）
|
Not recorded | GDY (5Z)-5-({4-[2-(thiophen-2-yl)ethoxy]phenyl}methylidene)-1,3-thiazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.8M SODIUM CITRATE, 100mM TRIS, pH 7.6
|
Resolution 2.15 Å R-free 0.264 |
| 6DH9 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with MSDC-0602 Deposited 2018-05-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
235–505（271 aa）
|
Not recorded | GH1 (5S)-5-({4-[2-(3-methoxyphenyl)-2-oxoethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione × 1 KNA nonanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 2.70 Å R-free 0.250 |
| 6DH9 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with MSDC-0602 Deposited 2018-05-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
235–505（271 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 2.70 Å R-free 0.250 |
| 6DHA Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Hydroxy Pioglitazone (M-IV) Deposited 2018-05-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
235–505（271 aa）
|
Not recorded | GFV Hydroxy Pioglitazone (M-IV) × 1 KNA nonanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.8M SODIUM CITRATE, 100mM TRIS, pH 7.6
|
Resolution 1.88 Å R-free 0.255 |
| 6DHA Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Hydroxy Pioglitazone (M-IV) Deposited 2018-05-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
235–505（271 aa）
|
Not recorded | GFV Hydroxy Pioglitazone (M-IV) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.8M SODIUM CITRATE, 100mM TRIS, pH 7.6
|
Resolution 1.88 Å R-free 0.255 |
| 6E5A PPARg in complex with compound 4b Deposited 2018-07-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
233–505（273 aa）
Chain B
233–505（273 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | HV4 (5Z)-5-({4-[(prop-2-yn-1-yl)oxy]phenyl}methylidene)-2-sulfanylidene-1,3-thiazolidin-4-one × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；289 K；1 M Na Citrate
|
Resolution 2.40 Å R-free 0.268 |
| 6ENQ Structure of human PPAR gamma LBD in complex with Lanifibranor (IVA337) Deposited 2017-10-06 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
224–505（282 aa）
Chain B
224–505（282 aa）
|
Not recorded | BJB 4-[1-(1,3-benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl]butanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；Na Citrate 0,9 M
1,2 - propanediol 3,5 %
Hepes 0,1 M
|
Resolution 2.20 Å R-free 0.271 |
| 6F2L Crystal structure of the complex between PPARgamma LBD and the ligand LJ570: structure obtained from crystals of the apo-form soaked for 15 days. Deposited 2017-11-24 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Chain B
223–505（283 aa）
|
Not recorded | AXY (2S)-3-(biphenyl-4-yl)-2-(biphenyl-4-yloxy)propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8 M NA CITRATE, 0.15 M TRIS, PH 8.0
|
Resolution 2.10 Å R-free 0.302 |
| 6FZF PPAR mutant complex Deposited 2018-03-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Mutation：T475M | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；290 K；25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Bis-Tris pH 6.5
|
Resolution 1.95 Å R-free 0.194 |
| 6FZF PPAR mutant complex Deposited 2018-03-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Mutation：T475M | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；290 K；25% PEG 3350, 0.2 M ammonium sulfate, 0.1 M Bis-Tris pH 6.5
|
Resolution 1.95 Å R-free 0.194 |
| 6FZG PPAR gamma mutant complex Deposited 2018-03-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
203–477（275 aa）
|
Mutation：I290M | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；290 K；25% PEG 3350, 0.2 M NaCl, 0.1 M Hepes pH 7.5
|
Resolution 2.10 Å R-free 0.208 |
| 6FZJ PPAR gamma mutant complex Deposited 2018-03-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Mutation：M280I | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 IOD IODIDE ION × 1 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；290 K；20% PEG 550 MME, 10% PEG 20 000, 30 mM sodium fluoride, 30 mM sodium bromide, 30 mM sodium iodide, 0.1 M sodium Hepes / MOPS pH 7.5
|
Resolution 2.01 Å R-free 0.226 |
| 6FZJ PPAR gamma mutant complex Deposited 2018-03-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Mutation：M280I | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 IOD IODIDE ION × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；290 K；20% PEG 550 MME, 10% PEG 20 000, 30 mM sodium fluoride, 30 mM sodium bromide, 30 mM sodium iodide, 0.1 M sodium Hepes / MOPS pH 7.5
|
Resolution 2.01 Å R-free 0.226 |
| 6FZP PPAR gamma complex. Deposited 2018-03-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；290 K；NH4 acetate 0.3M, Hepes 0.1M pH 7.5, di-sodium tartrate 0.8 M
|
Resolution 2.30 Å R-free 0.252 |
| 6FZY PPAR mutant Deposited 2018-03-15 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Chain B
231–505（275 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；290 K；0.5 M ammonium sulfate, 0.1 M PIPES pH7, 0.9 M disodium tartrate
|
Resolution 3.10 Å R-free 0.235 |
| 6ICJ Crystal structure of PPARgamma with compound BR102375K Deposited 2018-09-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
|
Not recorded | GOL GLYCEROL × 2 A0L 2-butyl-5-[(3-tert-butyl-1,2,4-oxadiazol-5-yl)methyl]-6-methyl-3-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl}pyrimidin-4(3H)-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.2 M NH4 Acetate, 0.1 M HEPES 7.5 pH, 25 %w/v PEG 3350
|
Resolution 2.48 Å R-free 0.282 |
| 6IJR Human PPARgamma ligand binding domain complexed with SB1495 Deposited 2018-10-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
|
Not recorded | A9C N-{[3-({[(1S,2R)-2-{[(2E)-2-cyano-4,4-dimethylpent-2-enoyl]amino}cyclopentyl]oxy}methyl)phenyl]methyl}-4-[(4-methylpiperazin-1-yl)methyl]benzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；295 K；60% (v/v) Tacsimate
|
Resolution 2.85 Å R-free 0.266 |
| 6IJR Human PPARgamma ligand binding domain complexed with SB1495 Deposited 2018-10-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
223–505（283 aa）
|
Not recorded | A9C N-{[3-({[(1S,2R)-2-{[(2E)-2-cyano-4,4-dimethylpent-2-enoyl]amino}cyclopentyl]oxy}methyl)phenyl]methyl}-4-[(4-methylpiperazin-1-yl)methyl]benzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；295 K；60% (v/v) Tacsimate
|
Resolution 2.85 Å R-free 0.266 |
| 6IJS Human PPARgamma ligand binding domain complexed with SB1494 Deposited 2018-10-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
232–505（274 aa）
|
Not recorded | A9F N-{[3-({[(1R,2S)-2-{[(2E)-2-cyano-4,4-dimethylpent-2-enoyl]amino}cyclopentyl]oxy}methyl)phenyl]methyl}-4-[(4-methylpiperazin-1-yl)methyl]benzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate
|
Resolution 2.15 Å R-free 0.241 |
| 6ILQ Crystal structure of PPARgamma with compound BR101549 Deposited 2018-10-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
|
Not recorded | AE0 ethyl [2-butyl-6-oxo-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl}-4-(propan-2-yl)-1,6-dihydropyrimidin-5-yl]acetate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.2 M MgCl2, 0.1 M TRIS 8.5 pH, 27 %w/v PEG 3350
|
Resolution 2.41 Å R-free 0.303 |
| 6IZM Crystal structure of the PPARgamma-LBD complexed with compound 1l Deposited 2018-12-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
|
Not recorded | B0X 3-[[6-(2,6-dimethylpyridin-3-yl)oxy-1-methyl-benzimidazol-2-yl]methoxy]benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, NaSCN, Tris-HCl
|
Resolution 1.80 Å R-free 0.248 |
| 6IZN Crystal structure of the PPARgamma-LBD complexed with compound 3g Deposited 2018-12-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
|
Not recorded | B1O 3-[[6-(2,6-dimethylpyridin-3-yl)oxy-7-fluoranyl-1-methyl-benzimidazol-2-yl]methoxy]benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；295 K；PEG 4000, NaSCN, Tris-HCl
|
Resolution 1.75 Å R-free 0.265 |
| 6JEY Covalent bond formation between ynone moiety of synthetic fatty acid and hPPARg-LBD Deposited 2019-02-07 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
232–505（274 aa）
Chain B
232–505（274 aa）
|
Not recorded | EJL (9Z,12Z,15Z,18Z,21Z)-5-oxidanylidenetetracosa-9,12,15,18,21-pentaen-6-ynoic acid × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1 M Tris-HCl pH 7.4, 0.8 M sodium citrate
|
Resolution 2.20 Å R-free 0.310 |
| 6JF0 Covalent labeling of hPPARg-LBD by turn-on fluorescent probe mediated by conjugate addition and cyclization Deposited 2019-02-07 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
232–505（274 aa）
Chain B
232–505（274 aa）
|
Not recorded | EB6 methyl (2~{S})-3-[4-[3-(4-methoxy-2-oxidanyl-phenyl)prop-2-ynoyloxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoate × 1 EBF 7-methoxychromen-2-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1 M Tris-HCl pH 7.4, 0.8 M sodium citrate
|
Resolution 3.40 Å R-free 0.296 |
| 6JQ7 The ligand-free structure of human PPARgamma LBD in the presence of the SRC-1 coactivator peptide Deposited 2019-03-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；60% (v/v) Tacsimate (pH 7.0)
|
Resolution 2.55 Å R-free 0.257 |
| 6K0T Crystal Structure of PPARgamma Ligand Binding Domain in complex with dibenzooxepine derivative compound-17 Deposited 2019-05-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | CTU 3-[(1~{E})-1-[8-[(8-chloranyl-2-cyclopropyl-imidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoranyl-6~{H}-benzo[c][1]benzoxepin-11-ylidene]ethyl]-4~{H}-1,2,4-oxadiazol-5-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.05M Magnesium acetate, 0.1M Sodium acetate, 12% PEG 8,000
|
Resolution 1.84 Å R-free 0.244 |
| 6K0T Crystal Structure of PPARgamma Ligand Binding Domain in complex with dibenzooxepine derivative compound-17 Deposited 2019-05-07 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
223–505（283 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | CTU 3-[(1~{E})-1-[8-[(8-chloranyl-2-cyclopropyl-imidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoranyl-6~{H}-benzo[c][1]benzoxepin-11-ylidene]ethyl]-4~{H}-1,2,4-oxadiazol-5-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.05M Magnesium acetate, 0.1M Sodium acetate, 12% PEG 8,000
|
Resolution 1.84 Å R-free 0.244 |
| 6KTM The ligand-free structure of human PPARgamma ligand-binding domain R288A mutant in the presence of the SRC-1 coactivator peptide Deposited 2019-08-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
|
Mutation：R316A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；2.2 M sodium malonate (pH 7.0)
|
Resolution 2.70 Å R-free 0.258 |
| 6KTN Human PPARgamma ligand-binding domain R288A mutant in complex with imatinib Deposited 2019-08-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
|
Mutation：R316A | STI 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；296 K；2.2 M sodium malonate (pH 7.0)
|
Resolution 2.75 Å R-free 0.256 |
| 6L89 Human PPARgamma ligand binding domain complexed with Butyrolactone 1 Deposited 2019-11-05 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Chain B
223–505（283 aa）
|
Not recorded | E7C methyl (2R)-3-(4-hydroxyphenyl)-2-[[3-(3-methylbut-2-enyl)-4-oxidanyl-phenyl]methyl]-4-oxidanyl-5-oxidanylidene-furan-2-carboxylate × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；1.2 M sodium citrate tribasic dihydrate, 0.1 M HEPES pH 7.5
|
Resolution 2.10 Å R-free 0.269 |
| 6L8B The ligand-free structure of human PPARgamma LBD Deposited 2019-11-05 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Chain B
223–505（283 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；1.2 M Sodium citrate tribasic dihydrate, 0.1 M HEPES pH 7.5
|
Resolution 2.10 Å R-free 0.268 |
| 6MCZ Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Arachidonic Acid Deposited 2018-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | ACD ARACHIDONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4
0.8M Sodium Citrate
|
Resolution 2.10 Å R-free 0.259 |
| 6MCZ Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Arachidonic Acid Deposited 2018-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
|
Not recorded | ACD ARACHIDONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4
0.8M Sodium Citrate
|
Resolution 2.10 Å R-free 0.259 |
| 6MD0 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Oleic Acid Deposited 2018-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | OLA OLEIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4
0.8M Sodium Citrate
|
Resolution 1.95 Å R-free 0.273 |
| 6MD0 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Oleic Acid Deposited 2018-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
|
Not recorded | OLA OLEIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4
0.8M Sodium Citrate
|
Resolution 1.95 Å R-free 0.273 |
| 6MD1 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Oleic acid Deposited 2018-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | OLA OLEIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4
0.8M Sodium Citrate
|
Resolution 2.20 Å R-free 0.266 |
| 6MD1 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Oleic acid Deposited 2018-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
|
Not recorded | OLA OLEIC ACID × 1 GW9 2-chloro-5-nitro-N-phenylbenzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4
0.8M Sodium Citrate
|
Resolution 2.20 Å R-free 0.266 |
| 6MD2 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Arachidonic acid Deposited 2018-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | GW9 2-chloro-5-nitro-N-phenylbenzamide × 1 ACD ARACHIDONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4
0.8M SODIUM CITRATE
|
Resolution 2.20 Å R-free 0.261 |
| 6MD2 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and Arachidonic acid Deposited 2018-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
|
Not recorded | GW9 2-chloro-5-nitro-N-phenylbenzamide × 1 ACD ARACHIDONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4
0.8M SODIUM CITRATE
|
Resolution 2.20 Å R-free 0.261 |
| 6MD4 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Rosiglitazone and Oleic acid Deposited 2018-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 OLA OLEIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4
0.8M SODIUM CITRATE
|
Resolution 2.24 Å R-free 0.282 |
| 6MD4 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Rosiglitazone and Oleic acid Deposited 2018-09-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4
0.8M SODIUM CITRATE
|
Resolution 2.24 Å R-free 0.282 |
| 6MS7 Peroxisome proliferator-activated receptor gamma ligand binding domain in complex with a novel selective PPAR-gamma modulator VSP-77 Deposited 2018-10-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
|
Not recorded | V77 {[(1S)-1-(4-chlorophenyl)octyl]oxy}acetic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；300 K；0.1 M of tri-sodium citrate (pH 5.5), 20% w/v PEG 3350
|
Resolution 1.43 Å R-free 0.208 |
| 6O67 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Mitoglitazone Deposited 2019-03-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | LO7 Mitoglitazone × 1 KNA nonanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 2.52 Å R-free 0.244 |
| 6O67 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Mitoglitazone Deposited 2019-03-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 2.52 Å R-free 0.244 |
| 6O68 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Ciglitazone Deposited 2019-03-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | LO4 Ciglitazone × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 2.78 Å R-free 0.298 |
| 6O68 Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with Ciglitazone Deposited 2019-03-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 2.78 Å R-free 0.298 |
| 6ONI Crystal structure of PPARgamma ligand binding domain in complex with N-CoR peptide and inverse agonist T0070907 Deposited 2019-04-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Not recorded | EEY 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate
0.1M MES, pH 6.5
30% w/v, PEG 8000
|
Resolution 1.80 Å R-free 0.226 |
| 6ONJ Crystal structure of PPARgamma ligand binding domain in complex with TRAP220 peptide and agonist rosiglitazone Deposited 2019-04-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；0.2M Sodium acetate trihydrate
0.1M Tris, pH 8.5
30% w/v, PEG 4000
|
Resolution 2.30 Å R-free 0.273 |
| 6PDZ Crystal structure of PPARgamma ligand binding domain in complex with SMRT peptide and inverse agonist T0070907 Deposited 2019-06-19 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
231–505（275 aa）
Chain B
231–505（275 aa）
|
Not recorded | EEY 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate
0.1M MES, pH 6.5
30% w/v PEG8000
|
Resolution 2.10 Å R-free 0.241 |
| 6QJ5 X-ray structure of PPARgamma LBD with the ligand NV1380 Deposited 2019-01-22 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Chain B
223–505（283 aa）
|
Not recorded | H8R (2~{S})-3-methyl-2-[(4-octoxyphenyl)carbonylamino]butanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8M NaCitrate, 0.15M Tris
|
Resolution 2.00 Å R-free 0.276 |
| 6T1S PPAR mutant Deposited 2019-10-05 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Mutation：F310S | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 2 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；290 K；25% PEG3350, 0.2 M LiSO4, BisTris 0.1M pH 6.5
|
Resolution 1.65 Å R-free 0.204 |
| 6T1V Structure of PPARg H494Y mutant in complex with GW1929 Deposited 2019-10-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Mutation：H494Y | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；290 K；0.2 M ammonium acetate, 0.1 M Hepes pH 7.5, trisodium citrate 1.2M
|
Resolution 2.21 Å R-free 0.196 |
| 6T6B Crystal structure of PPARgamma in complex with compound 16 (MF27) Deposited 2019-10-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | MLQ (2~{R})-2-[[6-[(2,4-dichlorophenyl)sulfonylamino]-1,3-benzothiazol-2-yl]sulfanyl]octanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293.15 K；33% PEG 3350, 0.15 M sodium citrate and 0.1 M tris, pH 8.0
|
Resolution 2.80 Å R-free 0.271 |
| 6T9C Crystal structure of the complex between PPARgamma LBD and the ligand NV1346 (3a) Deposited 2019-10-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Chain B
223–505（283 aa）
|
Not recorded | MX8 4-hexoxy-~{N}-[(2~{S})-3-methyl-1-(oxidanylamino)-1-oxidanylidene-butan-2-yl]benzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8 M Sodium Citrate, 0.15 M Tris
|
Resolution 1.95 Å R-free 0.262 |
| 6TDC PPAR gamma ligand binding domain in complex with MRL-871 Deposited 2019-11-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
207–477（271 aa）
|
Not recorded | 4F1 4-{1-[2-chloro-6-(trifluoromethyl)benzoyl]-1H-indazol-3-yl}benzoic acid × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.2 M Ammonium Nitrate, 20% w/v PEG3350
|
Resolution 2.33 Å R-free 0.239 |
| 6TSG Crystal structure of Peroxisome proliferator-activated receptor gamma (PPARG) in complex with TETRAC Deposited 2019-12-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | T4A 3,3',5,5'-TETRAIODOTHYROACETIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；33% PEG 3350 and 0.15 M sodium citrate
|
Resolution 2.98 Å R-free 0.292 |
| 6VZL Crystal structure of human PPARgamma ligand binding domain in complex with GW1929 Deposited 2020-02-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4, 0.8M SODIUM CITRATE
|
Resolution 2.07 Å R-free 0.289 |
| 6VZL Crystal structure of human PPARgamma ligand binding domain in complex with GW1929 Deposited 2020-02-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
|
Not recorded | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4, 0.8M SODIUM CITRATE
|
Resolution 2.07 Å R-free 0.289 |
| 6VZM Crystal structure of human PPARgamma ligand binding domain Y473E mutant in complex with Darglitazone Deposited 2020-02-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Mutation：Y473E | GEV (5Z)-5-({4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl}methylidene)-1,3-thiazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4, 0.8M SODIUM CITRATE
|
Resolution 2.40 Å R-free 0.278 |
| 6VZM Crystal structure of human PPARgamma ligand binding domain Y473E mutant in complex with Darglitazone Deposited 2020-02-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
|
Mutation：Y473E | GEV (5Z)-5-({4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl}methylidene)-1,3-thiazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4, 0.8M SODIUM CITRATE
|
Resolution 2.40 Å R-free 0.278 |
| 6VZN Crystal structure of human PPARgamma ligand binding domain Y473E mutant Deposited 2020-02-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Mutation：Y473E | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4, 0.8M SODIUM CITRATE
|
Resolution 2.30 Å R-free 0.278 |
| 6VZN Crystal structure of human PPARgamma ligand binding domain Y473E mutant Deposited 2020-02-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
|
Mutation：Y473E | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4, 0.8M SODIUM CITRATE
|
Resolution 2.30 Å R-free 0.278 |
| 6VZO Crystal structure of human PPARgamma ligand binding domain (Protein delipidated by denature and refold) Deposited 2020-02-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M Tris, pH 7.4
0.8M SODIUM CITRATE
|
Resolution 2.27 Å R-free 0.271 |
| 6VZO Crystal structure of human PPARgamma ligand binding domain (Protein delipidated by denature and refold) Deposited 2020-02-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M Tris, pH 7.4
0.8M SODIUM CITRATE
|
Resolution 2.27 Å R-free 0.271 |
| 6Y3U Crystal structure of PPARgamma in complex with compound (R)-16 Deposited 2020-02-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | MLQ (2~{R})-2-[[6-[(2,4-dichlorophenyl)sulfonylamino]-1,3-benzothiazol-2-yl]sulfanyl]octanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；33% PEG 3350, 0.1 M sodium citrate
|
Resolution 2.62 Å R-free 0.254 |
| 6ZLY Crystal structure of the complex between PPARgamma LBD and the ligand NV1362 (7a) Deposited 2020-07-01 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Chain B
223–505（283 aa）
|
Not recorded | QMH (2~{S})-2-[(4-hexoxyphenyl)carbonylamino]-3-methyl-butanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.8 M SODIUM CITRATE, 0.15 M TRIS, PH
8.0
|
Resolution 1.79 Å R-free 0.280 |
| 7A7H Crystal structure of PPARgamma in complex with compound TK90 Deposited 2020-08-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | TK9 (2~{R})-2-[[4-[[4-methoxy-2-(trifluoromethyl)phenyl]methylcarbamoyl]phenyl]methyl]butanoic acid × 1 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；27% PEG 3350, 0.2M Sodium citrate tribasic dehydrate
|
Resolution 2.40 Å R-free 0.255 |
| 7AHJ Crystal structure of PPARgamma V290M mutant ligand binding domain in complex with farglitazar Deposited 2020-09-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
232–505（274 aa）
Chain B
232–505（274 aa）
|
Mutation：V290M Mutation：V290M | 570 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1M TRIS pH8
0.92-1.2M Sodium Citrate
0.1mM TCEP
0.5 micro molar Farglitazar.
|
Resolution 2.10 Å R-free 0.237 |
| 7AWC Crystal structure of Peroxisome proliferator-activated receptor gamma (PPARG)in complex with rosiglitazone Deposited 2020-11-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 GOL GLYCEROL × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；1.4 M ammonium sulfate, 0.1 M tris, pH 7.5
|
Resolution 1.74 Å R-free 0.204 |
| 7AWD Crystal structure of Peroxisome proliferator-activated receptor gamma (PPARG)in complex with garcinoic acid Deposited 2020-11-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | NQD (2Z,6E,10E)-13-[(2R)-6-hydroxy-2,8-dimethyl-3,4-dihydro-2H-1-benzopyran-2-yl]-2,6,10-trimethyltrideca-2,6,10-trienoic acid × 2 CIT CITRIC ACID × 1 GOL GLYCEROL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；1.2 M ammonium sulfate, 0.1 M tris, pH 8.0
|
Resolution 1.93 Å R-free 0.230 |
| 7CXE The ligand-free structure of human PPARgamma LBD R280C mutant Deposited 2020-09-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Chain B
223–505（283 aa）
|
Mutation：R308C Mutation：R308C | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；1.2 M Sodium citrate tribasic dihydrate, 0.1 M HEPES pH 7.5
|
Resolution 2.50 Å R-free 0.265 |
| 7CXF The ligand-free structure of human PPARgamma LBD C285Y mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
|
Not recorded | MLA MALONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
|
Resolution 2.35 Å R-free 0.269 |
| 7CXG The ligand-free structure of human PPARgamma LBD Q286E mutant Deposited 2020-09-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Chain B
223–505（283 aa）
|
Mutation：Q314E Mutation：Q314E | GOL GLYCEROL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；1.2 M Sodium citrate tribasic dihydrate, 0.1 M HEPES pH 7.5
|
Resolution 1.88 Å R-free 0.231 |
| 7CXH The ligand-free structure of human PPARgamma LBD Q286E mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
|
Mutation：Q314E | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
|
Resolution 2.30 Å R-free 0.257 |
| 7CXI The ligand-free structure of human PPARgamma LBD F287Y mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
|
Not recorded | MLI MALONATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
|
Resolution 2.30 Å R-free 0.276 |
| 7CXJ The ligand-free structure of human PPARgamma LBD R288C mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
|
Mutation：R316C | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
|
Resolution 2.65 Å R-free 0.275 |
| 7CXK The ligand-free structure of human PPARgamma LBD R288H mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
|
Not recorded | MLI MALONATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
|
Resolution 2.20 Å R-free 0.264 |
| 7CXL The ligand-free structure of human PPARgamma LBD S289C mutant in the presence of the SRC-1 coactivator peptide Deposited 2020-09-01 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
|
Not recorded | MLA MALONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；295 K；2.2 M sodium malonate (pH 7.0)
|
Resolution 2.70 Å R-free 0.255 |
| 7E2O X-ray Crystal structure of PPARgamma R288H mutant. Deposited 2021-02-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
204–477（274 aa）
|
Mutation：R288H | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；0.1M Tris-HCl, 0.7M sodium citrate
|
Resolution 3.20 Å R-free 0.313 |
| 7E2O X-ray Crystal structure of PPARgamma R288H mutant. Deposited 2021-02-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
204–477（274 aa）
|
Mutation：R288H | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；298 K；0.1M Tris-HCl, 0.7M sodium citrate
|
Resolution 3.20 Å R-free 0.313 |
| 7EFQ Crystal structure of hPPARgamma ligand binding domain complexed with rosiglitazone-based fluorescence probe Deposited 2021-03-23 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
232–505（274 aa）
Chain B
232–505（274 aa）
|
Not recorded | J3F (5S)-5-[[4-[2-[[7-(diethylamino)-2-oxidanylidene-chromen-4-yl]-methyl-amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；One microliter of PPARgamma-LBD solution (6 mg/mL, in 20 mM Tris-HCl pH 8.0, 1 mM TCEP, 0.5 mM EDTA) with 0.5 equiv. ligand with 1 microliter of reservoir solution (0.8 M sodium citrate and 0.1 M Tris-HCl pH 7.3). Drops were equilibrated against 300 microliter of reservoir solution at 293K.
|
Resolution 2.30 Å R-free 0.264 |
| 7JQG Crystal structure of human PPARgamma ligand binding domain Y473E mutant in complex with GW1929 Deposited 2020-08-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Mutation：Y473E | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4, 0.8M SODIUM CITRATE
|
Resolution 2.15 Å R-free 0.270 |
| 7JQG Crystal structure of human PPARgamma ligand binding domain Y473E mutant in complex with GW1929 Deposited 2020-08-10 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
|
Mutation：Y473E | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；0.1M MOPS, pH 7.4, 0.8M SODIUM CITRATE
|
Resolution 2.15 Å R-free 0.270 |
| 7LOT Human PPAR Gamma LBD in Complex with Tetrazole Compound N-{3-[(4-methylbenzyl)oxy]benzyl}-2H-tetrazol-5-amine. Deposited 2021-02-10 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
232–505（274 aa）
Fragment：UNP residues 232-505
Chain B
232–505（274 aa）
Fragment：UNP residues 232-505
|
Not recorded | Y9A ~{N}-[[3-[(4-methylphenyl)methoxy]phenyl]methyl]-1~{H}-1,2,3,4-tetrazol-5-amine × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；291 K；100 mM HEPES, pH 7.0 and 0.85 M Sodium Citrate
|
Resolution 2.29 Å R-free 0.259 |
| 7P4E Crystal structure of PPARgamma in complex with compound FL217 Deposited 2021-07-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | 5IV ~{N}-[[4-(cyclopropylsulfonylamino)-2-(trifluoromethyl)phenyl]methyl]-1-[(3-fluorophenyl)methyl]indole-5-carboxamide × 1 SO4 SULFATE ION × 1 EDO 1,2-ETHANEDIOL × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；1.4M Ammonium sulfate, 0.1M Tris pH7.5
|
Resolution 2.40 Å R-free 0.268 |
| 7QB1 PPARg in complex with inhibitor Deposited 2021-11-17 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain AAA
223–505（283 aa）
Fragment：UNP residues 195-477
Chain BBB
223–505（283 aa）
Fragment：UNP residues 195-477
|
Not recorded | 9WQ 3-[(3,4-dichlorophenyl)methyl]-4-oxidanylidene-6-phenoxy-phthalazine-1-carboxylic acid × 2 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；20mM Tris pH 8.0, 5mM DTT, 100mM NaCl , 2mM EDTA
|
Resolution 2.20 Å R-free 0.249 |
| 7RLE Crystal structure of PPAR gamma in complex with CREB-binding protein and agonist GW1929 Deposited 2021-07-23 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
231–505（275 aa）
Chain C
231–505（275 aa）
|
Not recorded | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293.15 K；1M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate, pH 6.5
|
Resolution 2.50 Å R-free 0.275 |
| 7SQA PPAR gamma LBD bound to SR10221 and SMRT corepressor motif Deposited 2021-11-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | A8R (2S)-2-{5-[(5-{[(1S)-1-(4-tert-butylphenyl)ethyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]-2-chlorophenoxy}propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289 K；28% PEG 8,000, 0.1M Ammonium sulphate, 0.1M MES pH 6.5
|
Resolution 2.50 Å R-free 0.285 |
| 7SQA PPAR gamma LBD bound to SR10221 and SMRT corepressor motif Deposited 2021-11-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Not recorded | A8R (2S)-2-{5-[(5-{[(1S)-1-(4-tert-butylphenyl)ethyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]-2-chlorophenoxy}propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289 K；28% PEG 8,000, 0.1M Ammonium sulphate, 0.1M MES pH 6.5
|
Resolution 2.50 Å R-free 0.285 |
| 7SQB PPAR gamma LBD bound to Inverse Agonist SR10221 Deposited 2021-11-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | A8R (2S)-2-{5-[(5-{[(1S)-1-(4-tert-butylphenyl)ethyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]-2-chlorophenoxy}propanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.8；289 K；4.25M Ammonium acetate, 0.1M Bis Tris Propane pH 6.8
|
Resolution 2.60 Å R-free 0.261 |
| 7WOX PPARgamma antagonist (MMT-160)- PPARgamma LBD complex Deposited 2022-01-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
232–505（274 aa）
|
Not recorded | 5YW N-[[5-(3-phenylprop-2-ynoylamino)-2-propoxy-phenyl]methyl]-4-pyrimidin-2-yl-benzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1M Tris-HCl pH 7.4, 0.8M sodium citrate
|
Resolution 3.20 Å R-free 0.273 |
| 7WOX PPARgamma antagonist (MMT-160)- PPARgamma LBD complex Deposited 2022-01-22 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
232–505（274 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.1M Tris-HCl pH 7.4, 0.8M sodium citrate
|
Resolution 3.20 Å R-free 0.273 |
| 8ADF X-ray crystal structure of PPAR gamma ligand binding domain in complex with CZ39 Deposited 2022-07-08 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Chain B
223–504（282 aa）
|
Not recorded | LRA (2R)-3-(4-bromophenyl)-2-(3-hydroxyphenyl)-4-oxidanyl-2H-furan-5-one × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；0.8 M SODIUM CITRATE, 0.15 M TRIS, PH 8.0
|
Resolution 2.13 Å R-free 0.257 |
| 8AQM Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 6a) Deposited 2022-08-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | O2O 2-chloranyl-~{N}-[2-(3-methylphenyl)-1,3-benzoxazol-5-yl]-5-nitro-benzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1M MES pH 6, 0.2M NH4Cl, 20% PEG6000
|
Resolution 2.30 Å R-free 0.251 |
| 8AQM Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 6a) Deposited 2022-08-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Not recorded | O2O 2-chloranyl-~{N}-[2-(3-methylphenyl)-1,3-benzoxazol-5-yl]-5-nitro-benzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1M MES pH 6, 0.2M NH4Cl, 20% PEG6000
|
Resolution 2.30 Å R-free 0.251 |
| 8AQN Crystal structure of PPARG and NCOR2 with BAY-4931, an inverse agonist (compound 6c) Deposited 2022-08-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | O0U 2-chloranyl-~{N}-[2-(4-ethylphenyl)-1,3-benzoxazol-5-yl]-5-nitro-benzamide × 1 GOL GLYCEROL × 2 CA CALCIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 0.2 M Ca acetate, 20% PEG8000
|
Resolution 1.90 Å R-free 0.218 |
| 8AQN Crystal structure of PPARG and NCOR2 with BAY-4931, an inverse agonist (compound 6c) Deposited 2022-08-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Not recorded | O0U 2-chloranyl-~{N}-[2-(4-ethylphenyl)-1,3-benzoxazol-5-yl]-5-nitro-benzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M MES pH 6.0, 0.2 M Ca acetate, 20% PEG8000
|
Resolution 1.90 Å R-free 0.218 |
| 8ATY Crystal structure of PPAR gamma (PPARG) in complex with JP85 (compound 1). Deposited 2022-08-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | O7O 2-[4-chloranyl-6-(5,6,7,8-tetrahydronaphthalen-1-ylamino)pyrimidin-2-yl]sulfanylethanoic acid × 2 GOL GLYCEROL × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293.15 K；1.4 M Ammonium sulfate, 0.1 M tris pH 8.0
|
Resolution 1.90 Å R-free 0.201 |
| 8ATZ Crystal structure of PPAR gamma (PPARG) in complex with SA112 (compound 2). Deposited 2022-08-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | GOL GLYCEROL × 1 O86 2-[4-chloranyl-6-[[3-(2-phenylethoxy)phenyl]amino]pyrimidin-2-yl]sulfanylethanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293.15 K；1.6 M ammonium sulfate, 0.1 M tris pH 7.5
|
Resolution 1.95 Å R-free 0.245 |
| 8B8W Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7a) Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | Q2X 4-chloranyl-~{N}3-phenyl-~{N}1-(phenylmethyl)benzene-1,3-dicarboxamide × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 4000 24%, NaCl 0.2 M, Hepes 0.1 M (pH 7.5)
|
Resolution 1.86 Å R-free 0.275 |
| 8B8W Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7a) Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Not recorded | Q2X 4-chloranyl-~{N}3-phenyl-~{N}1-(phenylmethyl)benzene-1,3-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 4000 24%, NaCl 0.2 M, Hepes 0.1 M (pH 7.5)
|
Resolution 1.86 Å R-free 0.275 |
| 8B8X Crystal structure of PPARG and NCOR2 with SR10221, an inverse agonist Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | A8R (2S)-2-{5-[(5-{[(1S)-1-(4-tert-butylphenyl)ethyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]-2-chlorophenoxy}propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, K/Na tartrate 0.2 M
|
Resolution 1.78 Å R-free 0.216 |
| 8B8X Crystal structure of PPARG and NCOR2 with SR10221, an inverse agonist Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Not recorded | A8R (2S)-2-{5-[(5-{[(1S)-1-(4-tert-butylphenyl)ethyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]-2-chlorophenoxy}propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, K/Na tartrate 0.2 M
|
Resolution 1.78 Å R-free 0.216 |
| 8B8Y Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7e) Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | Q33 4,5-bis(chloranyl)-~{N}3-phenyl-~{N}1-(phenylmethyl)benzene-1,3-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, HCOOMg 0.2 M
|
Resolution 2.00 Å R-free 0.242 |
| 8B8Y Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7e) Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Not recorded | Q33 4,5-bis(chloranyl)-~{N}3-phenyl-~{N}1-(phenylmethyl)benzene-1,3-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, HCOOMg 0.2 M
|
Resolution 2.00 Å R-free 0.242 |
| 8B8Z Crystal structure of mutant PPARG (C313A) and NCOR2 with an inverse agonist (compound 7e) Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Mutation：C313A | Q33 4,5-bis(chloranyl)-~{N}3-phenyl-~{N}1-(phenylmethyl)benzene-1,3-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, HCOONa 0.2 M
|
Resolution 2.22 Å R-free 0.248 |
| 8B8Z Crystal structure of mutant PPARG (C313A) and NCOR2 with an inverse agonist (compound 7e) Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Mutation：C313A | Q33 4,5-bis(chloranyl)-~{N}3-phenyl-~{N}1-(phenylmethyl)benzene-1,3-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, HCOONa 0.2 M
|
Resolution 2.22 Å R-free 0.248 |
| 8B90 Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7d) Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | Q1R 5-chloranyl-~{N}3-phenyl-~{N}1-(phenylmethyl)benzene-1,3-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, LiNO3 0.2 M
|
Resolution 2.10 Å R-free 0.274 |
| 8B90 Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 7d) Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, LiNO3 0.2 M
|
Resolution 2.10 Å R-free 0.274 |
| 8B91 Crystal structure of mutant PPARG (C313A) and NCOR2 with an inverse agonist (compound SI-1) Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Mutation：C313A | Q4O ~{N}3-[4-[bis(fluoranyl)methoxy]-3-fluoranyl-phenyl]-4-chloranyl-6-fluoranyl-~{N}1-[(2-methoxyphenyl)methyl]benzene-1,3-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, NaAc 0.2 M
|
Resolution 2.23 Å R-free 0.228 |
| 8B91 Crystal structure of mutant PPARG (C313A) and NCOR2 with an inverse agonist (compound SI-1) Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Mutation：C313A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, NaAc 0.2 M
|
Resolution 2.23 Å R-free 0.228 |
| 8B92 Crystal structure of PPARG and NCOR2 with an inverse agonist (compound SI-2) Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | Q5X 4-chloranyl-6-fluoranyl-~{N}3-[2-fluoranyl-4-(oxetan-3-yl)phenyl]-~{N}1-[(2-methoxyphenyl)methyl]benzene-1,3-dicarboxamide × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 6000 25%, TRIS 0.1 M (pH 8.0), ZnCl 0.01 M
|
Resolution 1.66 Å R-free 0.227 |
| 8B92 Crystal structure of PPARG and NCOR2 with an inverse agonist (compound SI-2) Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Not recorded | Q5X 4-chloranyl-6-fluoranyl-~{N}3-[2-fluoranyl-4-(oxetan-3-yl)phenyl]-~{N}1-[(2-methoxyphenyl)methyl]benzene-1,3-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 6000 25%, TRIS 0.1 M (pH 8.0), ZnCl 0.01 M
|
Resolution 1.66 Å R-free 0.227 |
| 8B93 Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 15b) Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | Q8F 4-chloranyl-6-fluoranyl-~{N}1-[[4-fluoranyl-2-(2-methoxyethoxymethyl)phenyl]methyl]-~{N}3-[2-methyl-4-(trifluoromethyl)phenyl]benzene-1,3-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, HCOONa 0.2 M
|
Resolution 2.21 Å R-free 0.386 |
| 8B93 Crystal structure of PPARG and NCOR2 with an inverse agonist (compound 15b) Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Not recorded | Q8F 4-chloranyl-6-fluoranyl-~{N}1-[[4-fluoranyl-2-(2-methoxyethoxymethyl)phenyl]methyl]-~{N}3-[2-methyl-4-(trifluoromethyl)phenyl]benzene-1,3-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, HCOONa 0.2 M
|
Resolution 2.21 Å R-free 0.386 |
| 8B94 Crystal structure of PPARG and NCOR2 with BAY-5516, an inverse agonist Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | Q5O ~{N}3-[4-[bis(fluoranyl)methoxy]-2-methyl-phenyl]-4-chloranyl-6-fluoranyl-~{N}1-[(4-fluorophenyl)methyl]benzene-1,3-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, HCOOK 0.2 M
|
Resolution 1.55 Å R-free 0.240 |
| 8B94 Crystal structure of PPARG and NCOR2 with BAY-5516, an inverse agonist Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Not recorded | Q5O ~{N}3-[4-[bis(fluoranyl)methoxy]-2-methyl-phenyl]-4-chloranyl-6-fluoranyl-~{N}1-[(4-fluorophenyl)methyl]benzene-1,3-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, HCOOK 0.2 M
|
Resolution 1.55 Å R-free 0.240 |
| 8B95 Crystal structure of PPARG and NCOR2 with BAY-9683, an inverse agonist Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | Q4C ~{N}1-[[3,4-bis(fluoranyl)phenyl]methyl]-4-chloranyl-6-fluoranyl-~{N}3-(3-methyl-5-morpholin-4-yl-pyridin-2-yl)benzene-1,3-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, BT Prop 0.1 M (pH 7.5), NaAc 0.2 M
|
Resolution 1.72 Å R-free 0.238 |
| 8B95 Crystal structure of PPARG and NCOR2 with BAY-9683, an inverse agonist Deposited 2022-10-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Not recorded | Q4C ~{N}1-[[3,4-bis(fluoranyl)phenyl]methyl]-4-chloranyl-6-fluoranyl-~{N}3-(3-methyl-5-morpholin-4-yl-pyridin-2-yl)benzene-1,3-dicarboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350 20%, BT Prop 0.1 M (pH 7.5), NaAc 0.2 M
|
Resolution 1.72 Å R-free 0.238 |
| 8BF1 High-resolution structure of unliganded PPAR gamma in complex with the peptide PGC-1 alpha Deposited 2022-10-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292.15 K；0.1 M Bis-Tris pH 6.5
0.2 M ammonium acetate
0.01 M gunidine hydrochloride
|
Resolution 1.36 Å R-free 0.181 |
| 8BF2 Human PPARgamma in complex with MEHP bound to the AF-2 and omega sub-pockets Deposited 2022-10-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
234–505（272 aa）
|
Not recorded | QGL 2-[(2~{S})-2-ethylhexoxy]carbonylbenzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；292.15 K；0.1 M Tris pH, 7.6
0.8 M sodium citrate
|
Resolution 2.18 Å R-free 0.247 |
| 8BF2 Human PPARgamma in complex with MEHP bound to the AF-2 and omega sub-pockets Deposited 2022-10-23 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
234–505（272 aa）
|
Not recorded | QGL 2-[(2~{S})-2-ethylhexoxy]carbonylbenzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.6；292.15 K；0.1 M Tris pH, 7.6
0.8 M sodium citrate
|
Resolution 2.18 Å R-free 0.247 |
| 8BFF Human PPARgamma in complex with MINCH bound to the AF-2 sub-pocket Deposited 2022-10-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
234–505（272 aa）
|
Not recorded | QG6 (1~{S},2~{R})-2-[(4~{R})-4-methylheptoxy]carbonylcyclohexane-1-carboxylic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292.15 K；0.1 M Tris-HCl pH 8.5
30% PEG 2000
0.2 M Lithium sulfate
0.01 M guanidine hydrochloride
|
Resolution 2.60 Å R-free 0.295 |
| 8BFF Human PPARgamma in complex with MINCH bound to the AF-2 sub-pocket Deposited 2022-10-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
234–505（272 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292.15 K；0.1 M Tris-HCl pH 8.5
30% PEG 2000
0.2 M Lithium sulfate
0.01 M guanidine hydrochloride
|
Resolution 2.60 Å R-free 0.295 |
| 8BFF Human PPARgamma in complex with MINCH bound to the AF-2 sub-pocket Deposited 2022-10-25 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain C
234–505（272 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292.15 K；0.1 M Tris-HCl pH 8.5
30% PEG 2000
0.2 M Lithium sulfate
0.01 M guanidine hydrochloride
|
Resolution 2.60 Å R-free 0.295 |
| 8C0C X-ray crystal structure of PPAR gamma ligand binding domain in complex with CZ46 Deposited 2022-12-16 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Chain B
223–504（282 aa）
|
Not recorded | T0C (2~{R})-2-[4-(naphthalen-1-ylmethoxy)phenyl]-4-oxidanyl-3-phenyl-2~{H}-furan-5-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；0.8 M SODIUM CITRATE, 0.15 M TRIS, PH 8.0
|
Resolution 2.20 Å R-free 0.272 |
| 8CPH Crystal structure of PPAR gamma (PPARG) in complex with WY-14643 (inactive form) Deposited 2023-03-02 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Chain B
231–505（275 aa）
|
Not recorded | WY1 2-({4-CHLORO-6-[(2,3-DIMETHYLPHENYL)AMINO]PYRIMIDIN-2-YL}SULFANYL)ACETIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；30% PEG 3350, 0.15M sodium citrate
|
Resolution 2.40 Å R-free 0.263 |
| 8CPI Crystal structure of PPAR gamma (PPARG) in complex with WY-14643 Deposited 2023-03-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | WY1 2-({4-CHLORO-6-[(2,3-DIMETHYLPHENYL)AMINO]PYRIMIDIN-2-YL}SULFANYL)ACETIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；1.6M ammonium sulfate, 0.1M tris 8.0
|
Resolution 2.10 Å R-free 0.282 |
| 8CPJ Crystal structure of PPAR gamma (PPARG) in an inactive form Deposited 2023-03-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293.15 K；27% PEG 3350, 0.15M sodium citrate
|
Resolution 2.40 Å R-free 0.282 |
| 8DK4 Peroxisome proliferator-activated receptor gamma in complex with VSP-51-2 Deposited 2022-07-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Fragment：ligand binding domain (UNP residues 234-505)
|
Not recorded | SJ9 5-(benzylcarbamoyl)-1-[(4-chloro-3-fluorophenyl)methyl]-1H-indole-2-carboxylic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1 M of trisodium citrate, pH 5.5, 20% w/v PEG3350
|
Resolution 2.60 Å R-free 0.255 |
| 8DKN PPARg bound to T0070907 and Co-R peptide Deposited 2022-07-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
|
Not recorded | EEY 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide × 1 CXS 3-CYCLOHEXYL-1-PROPYLSULFONIC ACID × 2 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9.5；296 K；2+2 uL drops made from a 2:2:1 molar ratio of T007:NCOR peptide:PPARg and well solution containing 1.8-2.2 M (NH3)2SO4, 0.2 M Li2SO4 and 100 mM CAPS pH 9.5. Protein formulated at 20 mg mL-1 in 20 mM Tris, pH 8.0, 100 mM NaCl, and 1mM TCEP
|
Resolution 1.95 Å R-free 0.297 |
| 8DKV PPARg bound to JTP-426467 and Co-R peptide Deposited 2022-07-06 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
|
Not recorded | SKL 2-chloro-N-[4-(5-methyl-1,3-benzoxazol-2-yl)phenyl]-5-nitrobenzamide × 1 CXS 3-CYCLOHEXYL-1-PROPYLSULFONIC ACID × 2 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；296 K；2+2 uL drops made from a 2:2:1 molar ratio of JTP-4:NCOR peptide:PPARg and well solution containing 1.8-2.2 M (NH3)2SO4, 0.2 M Li2SO4 and 100 mM CAPS pH 9.5. Protein formulated at 20 mg mL-1 in 20 mM Tris, pH 8.0, 100 mM NaCl, and 1mM TCEP
|
Resolution 1.59 Å R-free 0.266 |
| 8DSY PPARg bound to inverse agonist H3B-343 Deposited 2022-07-24 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Chain B
234–505（272 aa）
|
Not recorded | TJC {5-[(5-{[(4-tert-butylphenyl)methyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]-2-chlorophenoxy}acetic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；296 K；2+2 uL drops of protein + reservoir consisting of 0.9-1.2 M Na citrate and 100 mM Tris pH 8.0. Protein formulated at 20 mg mL-1 in 20 mM Tris, pH 8.0, 100 mM NaCl, and 1mM TCEP
|
Resolution 2.95 Å R-free 0.267 |
| 8DSZ PPARg bound to partial agonist H3B-487 Deposited 2022-07-24 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Chain B
234–505（272 aa）
|
Not recorded | TJO (2R)-2-{5-[(5-{[(1R)-1-(4-tert-butylphenyl)ethyl]carbamoyl}-2,3-dimethyl-1H-indol-1-yl)methyl]-2-chlorophenoxy}propanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；296 K；2 + 2 uL drops containing protein + reservoir solution containing 0.9-1.2 M Na citrate and 100 mM Tris pH 8.0. Protein formulated in 20 mg mL-1 in 20 mM Tris, pH 8.0, 100 mM NaCl, and 1mM TCEP
|
Resolution 2.50 Å R-free 0.269 |
| 8FHE Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and GW9662 Deposited 2022-12-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Not recorded | GW9 2-chloro-5-nitro-N-phenylbenzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
|
Resolution 1.80 Å R-free 0.229 |
| 8FHF Crystal structure of PPARgamma ligand-binding domain in complex with ZINC5672437 Deposited 2022-12-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | XZK N-(4-carbamoylphenyl)-2-chloro-5-nitrobenzamide × 1 KNA nonanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
|
Resolution 2.10 Å R-free 0.285 |
| 8FHF Crystal structure of PPARgamma ligand-binding domain in complex with ZINC5672437 Deposited 2022-12-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
231–505（275 aa）
|
Not recorded | XZK N-(4-carbamoylphenyl)-2-chloro-5-nitrobenzamide × 1 KNA nonanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
|
Resolution 2.10 Å R-free 0.285 |
| 8FHG Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and ZINC5672437 Deposited 2022-12-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Not recorded | XZK N-(4-carbamoylphenyl)-2-chloro-5-nitrobenzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
|
Resolution 1.80 Å R-free 0.234 |
| 8FKC Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and inverse agonist SR33544 Deposited 2022-12-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | Y5F 2-chloro-N-(5-cyanopyridin-3-yl)-5-nitrobenzamide × 1 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
|
Resolution 1.42 Å R-free 0.198 |
| 8FKD Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and inverse agonist SR33068 Deposited 2022-12-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | Y5O 2-chloro-N-(6-cyanopyridin-3-yl)-5-nitrobenzamide × 1 EDO 1,2-ETHANEDIOL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
|
Resolution 2.22 Å R-free 0.251 |
| 8FKE Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and inverse agonist SR32904 Deposited 2022-12-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | Y5T 2-chloro-N-(2-methylpyridin-4-yl)-5-nitrobenzamide × 1 EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
|
Resolution 2.02 Å R-free 0.249 |
| 8FKF Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and inverse agonist SR36706 Deposited 2022-12-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | Y5X 2-chloro-N-(5-fluoropyridin-3-yl)-5-nitrobenzamide × 1 EDO 1,2-ETHANEDIOL × 4 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
|
Resolution 1.82 Å R-free 0.216 |
| 8FKG Crystal structure of PPARgamma ligand-binding domain in complex with N-CoR peptide and inverse agonist SR33486 Deposited 2022-12-21 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | GOL GLYCEROL × 2 Y62 2-chloro-N-(5-cyanopyridin-2-yl)-5-nitrobenzamide × 1 SO4 SULFATE ION × 1 EDO 1,2-ETHANEDIOL × 8 K POTASSIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.2M Ammonium sulfate, 0.1M MES, pH 6.5, 30% w/v, PEG 8000
|
Resolution 2.12 Å R-free 0.218 |
| 8HHP Crystal structure of PPARg-LBD complexed with three partial agonists, one nTZDpa and two LT175 Deposited 2022-11-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
204–477（274 aa）
|
Not recorded | NZA 5-CHLORO-1-(4-CHLOROBENZYL)-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID × 1 LRG (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.7；293 K；0.1 M Tris-HCl pH 7.7, 0.75 M sodium citrate
|
Resolution 2.45 Å R-free 0.286 |
| 8HHQ Covalent bond formation between cysteine of PPARg-LBD and iodoacetic acid Deposited 2022-11-16 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
204–477（274 aa）
Chain B
204–477（274 aa）
|
Not recorded | GOA GLYCOLIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；0.1 M Tris-HCl pH 7.4, 0.8 M sodium citrate
|
Resolution 2.40 Å R-free 0.266 |
| 8PBO Deep interactome learning for generative drug design Deposited 2023-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
232–505（274 aa）
|
Not recorded | Y5I 3-[2-fluoranyl-4-[3-[2-fluoranyl-4-(5-methyl-1,3,4-thiadiazol-2-yl)phenoxy]propoxy]phenyl]propanoic acid × 1 GOL GLYCEROL × 3 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；1.6 M Ammoniumsulphate, 0.1 M Tris/HCl pH 7.5
|
Resolution 1.85 Å R-free 0.213 |
| 8PBO Deep interactome learning for generative drug design Deposited 2023-06-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
232–505（274 aa）
|
Not recorded | GOL GLYCEROL × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；1.6 M Ammoniumsulphate, 0.1 M Tris/HCl pH 7.5
|
Resolution 1.85 Å R-free 0.213 |
| 8REJ Crystal structure of PPAR gamma Ligand Binding Domain in complex with the ligand LBB78 Deposited 2023-12-11 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–505（283 aa）
Chain B
223–505（283 aa）
|
Not recorded | WUE (2~{S})-2-(4-naphthalen-1-ylphenoxy)-3-phenyl-propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.8 M Na citrate, 0.15 M Tris
|
Resolution 3.16 Å R-free 0.266 |
| 8SC9 Structure of PPARG in complex with MTX-531 Deposited 2023-04-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
232–505（274 aa）
Fragment：UNP residues 232-505
|
Not recorded | SO4 SULFATE ION × 5 TAM TRIS(HYDROXYETHYL)AMINOMETHANE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；293 K；2.2 M Ammonium Sulfate, 0.1 M BIS-TRIS-Propane pH 9.0
|
Resolution 1.85 Å R-free 0.241 |
| 8SC9 Structure of PPARG in complex with MTX-531 Deposited 2023-04-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
232–505（274 aa）
Fragment：UNP residues 232-505
|
Not recorded | SO4 SULFATE ION × 5 D0D N-[(5P)-2-chloro-5-(4-{[(1R)-1-phenylethyl]amino}quinazolin-6-yl)pyridin-3-yl]methanesulfonamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；293 K；2.2 M Ammonium Sulfate, 0.1 M BIS-TRIS-Propane pH 9.0
|
Resolution 1.85 Å R-free 0.241 |
| 8U57 PPARg LBD in complex with perfluorooctanoic acid (PFOA) Deposited 2023-09-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
203–477（275 aa）
Fragment：Ligand binding domain
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | 8PF pentadecafluorooctanoic acid × 4 D1D (4S,5S)-1,2-DITHIANE-4,5-DIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；289.15 K；0.6 - 1.2 M sodium citrate tribasic dihydrate, 0.1 M Tris 8.0
|
Resolution 2.00 Å R-free 0.254 |
| 8WFE The Crystal Structure of PPARg from Biortus. Deposited 2023-09-19 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Chain B
234–505（272 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 PEG DI(HYDROXYETHYL)ETHER × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1M MIB pH9.0, 25% PEG 1500
|
Resolution 2.20 Å R-free 0.248 |
| 8ZFN Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and BVT.13 Deposited 2024-05-08 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Chain B
231–505（275 aa）
|
Not recorded | GW9 2-chloro-5-nitro-N-phenylbenzamide × 2 PLB 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 2.54 Å R-free 0.321 |
| 8ZFO Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and nTZDpa Deposited 2024-05-08 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Chain B
231–505（275 aa）
|
Not recorded | NZA 5-CHLORO-1-(4-CHLOROBENZYL)-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID × 2 GW9 2-chloro-5-nitro-N-phenylbenzamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 3.15 Å R-free 0.296 |
| 8ZFP Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with GW9662 and MRL24 Deposited 2024-05-08 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Chain B
231–505（275 aa）
|
Not recorded | GW9 2-chloro-5-nitro-N-phenylbenzamide × 2 241 (2S)-2-(3-{[1-(4-METHOXYBENZOYL)-2-METHYL-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL]METHYL}PHENOXY)PROPANOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 2.48 Å R-free 0.303 |
| 8ZFQ Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with T0070907 and BVT.13 Deposited 2024-05-08 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Chain B
231–505（275 aa）
|
Not recorded | EEY 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide × 2 PLB 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 2.49 Å R-free 0.304 |
| 8ZFR Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with T0070907 and nTZDpa Deposited 2024-05-08 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Chain B
231–505（275 aa）
|
Not recorded | EEY 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide × 1 NZA 5-CHLORO-1-(4-CHLOROBENZYL)-3-(PHENYLTHIO)-1H-INDOLE-2-CARBOXYLIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 2.73 Å R-free 0.302 |
| 8ZFS Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with T0070907 and MRL24 Deposited 2024-05-08 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Chain B
231–505（275 aa）
|
Not recorded | EEY 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide × 2 241 (2S)-2-(3-{[1-(4-METHOXYBENZOYL)-2-METHYL-5-(TRIFLUOROMETHOXY)-1H-INDOL-3-YL]METHYL}PHENOXY)PROPANOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.6；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 2.56 Å R-free 0.271 |
| 8ZFT Crystal Structure of Human PPARgamma Ligand Binding Domain in Complex with T0070907 and SR1664 Deposited 2024-05-08 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
Chain B
231–505（275 aa）
|
Not recorded | EEY 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide × 2 3JX 4'-[(2,3-dimethyl-5-{[(1S)-1-(4-nitrophenyl)ethyl]carbamoyl}-1H-indol-1-yl)methyl]biphenyl-2-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.8M SODIUM CITRATE, 100mM MOPS, pH 7.6
|
Resolution 3.20 Å R-free 0.280 |
| 9CK0 Cocrystal of PPARg LBD and NFKBIB / IKBB peptide with agonist GW1929 Deposited 2024-07-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；295.15 K；0.2 M LIthium sulfate, 0.1 M Tris pH 8.5, 16% (w/v) PEG 4000
|
Resolution 2.60 Å R-free 0.296 |
| 9CWN NRIP1_133 / RIP140 SxxLxxLL motif coregulator peptide with agonist GW1929 and PPARg LBD Deposited 2024-07-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | EDK (2~{S})-3-[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]-2-[[2-(phenylcarbonyl)phenyl]amino]propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；293.15 K；1.6 M AmSO4, 100mM Tris pH 8.5
|
Resolution 2.70 Å R-free 0.242 |
| 9F7W Human PPARgamma ligand binding domain in complex with co-activator 1alpha peptide and bisphenol A (BPA) Deposited 2024-05-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
|
Not recorded | 2OH 4,4'-PROPANE-2,2-DIYLDIPHENOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；292.15 K；20% w/v PEG 3350, 0.2 M magnesium acetate, 137 mM sodium chloride, 8.1 mM disodium hydrogen phosphate, 1.5 mM potassium dihydrogen phosphate, 2.7 mM potassium chloride, 1 mM peptide, 15 mM BPB, 1.5 % DMSO
|
Resolution 1.25 Å R-free 0.189 |
| 9F7X Human PPARgamma ligand binding domain in complex with co-activator 1alpha peptide and bisphenol B (BPB) Deposited 2024-05-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
|
Not recorded | H3W bisphenol-B × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；292.15 K；20% w/v PEG 3350, 0.337 M sodium chloride, 8.1 mM disodium hydrogen phosphate, 1.5 mM potassium dihydrogen phosphate, 2.7 mM potassium chloride, 1 mM peptide, 15 mM BPB, 1.5 % DMSO
|
Resolution 1.63 Å R-free 0.290 |
| 9GFU Human PPAR-gamma ligand binding domain in complex with AKGO172 Deposited 2024-08-12 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IK6 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(3-ethoxycarbonylphenyl)methoxy]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.10 Å R-free 0.250 |
| 9GVP Human PPAR-gamma ligand binding domain in complex with WG115 Deposited 2024-09-25 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–503（269 aa）
Chain B
235–503（269 aa）
|
Not recorded | A1IPP 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.05 Å R-free 0.249 |
| 9GVS Human PPAR-gamma ligand binding domain in complex with AK176_C Deposited 2024-09-25 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IPR 4-[1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-6-(trifluoromethyl)indazol-3-yl]-3-phenylmethoxy-benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.10 Å R-free 0.255 |
| 9GVT Human PPAR-gamma ligand binding domain in complex with AK176_D Deposited 2024-09-25 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IPQ 4-[1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-5-(trifluoromethyloxy)indazol-3-yl]-3-phenylmethoxy-benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.30 Å R-free 0.252 |
| 9GW3 Human PPAR-gamma ligand binding domain in complex with LW56 Deposited 2024-09-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IPW 4-[1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-5-methyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.00 Å R-free 0.252 |
| 9GW4 Human PPAR-gamma ligand binding domain in complex with LW78 Deposited 2024-09-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IPS 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(2,3-dimethoxyphenyl)methoxy]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.20 Å R-free 0.248 |
| 9GW7 Human PPAR-gamma ligand binding domain in complex with LW76 Deposited 2024-09-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IPU 3-(1,3-benzodioxol-5-ylmethoxy)-4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.10 Å R-free 0.248 |
| 9GW8 Human PPAR-gamma ligand binding domain in complex with LW75 Deposited 2024-09-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IRG 3-(1,3-benzodioxol-4-ylmethoxy)-4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.20 Å R-free 0.257 |
| 9GWB Human PPAR-gamma ligand binding domain in complex with LW69 Deposited 2024-09-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IPZ 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-(oxan-4-ylmethoxy)benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.20 Å R-free 0.245 |
| 9GWC Human PPAR-gamma ligand binding domain in complex with LW99 Deposited 2024-09-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IPX 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[[(2~{S})-oxan-2-yl]methoxy]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.00 Å R-free 0.247 |
| 9GWE Human PPAR-gamma ligand binding domain in complex with LW87 Deposited 2024-09-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IPV 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[[3-(trifluoromethyloxy)phenyl]methoxy]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.10 Å R-free 0.259 |
| 9GWF Human PPAR-gamma ligand binding domain in complex with LW100 Deposited 2024-09-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IPT 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[[3-(methylcarbamoyl)phenyl]methoxy]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.40 Å R-free 0.253 |
| 9GWG Human PPAR-gamma ligand binding domain in complex with LW88 Deposited 2024-09-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IP1 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]methoxy]benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.30 Å R-free 0.252 |
| 9GWH Human PPAR-gamma ligand binding domain in complex with LW77 Deposited 2024-09-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IP0 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-2-phenylmethoxy-benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.10 Å R-free 0.256 |
| 9GWI Human PPAR-gamma ligand binding domain in complex with LW23 Deposited 2024-09-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IPY 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-(phenoxymethyl)benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.20 Å R-free 0.253 |
| 9GWK Human PPAR-gamma ligand binding domain in complex with AKGO6A Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IP9 4-[7-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.20 Å R-free 0.254 |
| 9GWL Human PPAR-gamma ligand binding domain in complex with AKGO157 Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IP7 4-[6-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.20 Å R-free 0.249 |
| 9GWM Human PPAR-gamma ligand binding domain in complex with AKGO108 Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IP6 4-[1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-6-cyano-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.20 Å R-free 0.253 |
| 9GWN Human PPAR-gamma ligand binding domain in complex with LW30 Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IP4 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-(phenylazanylmethyl)benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.20 Å R-free 0.258 |
| 9GWP Human PPAR-gamma ligand binding domain in complex with MRL-871 with two distinct binding modes Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | 4F1 4-{1-[2-chloro-6-(trifluoromethyl)benzoyl]-1H-indazol-3-yl}benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.55 Å R-free 0.269 |
| 9GWQ Human PPAR-gamma ligand binding domain in complex with AKGO6D Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQA 4-[1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-5-cyano-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.10 Å R-free 0.255 |
| 9GWR Human PPAR-gamma ligand binding domain in complex with AKGO10 Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IP3 4-[5-chloranyl-1-(2-chlorophenyl)carbonyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.10 Å R-free 0.255 |
| 9GWS Human PPAR-gamma ligand binding domain in complex with AKGO8 Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQB 4-[5-chloranyl-1-[2-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.20 Å R-free 0.237 |
| 9GWX Human PPAR-gamma ligand binding domain in complex with AKGO141 Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IP8 4-[1-[2,6-bis(chloranyl)phenyl]carbonyl-5-chloranyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.20 Å R-free 0.248 |
| 9GWY Human PPAR-gamma ligand binding domain in complex with AKGO78 Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQD 4-[5-chloranyl-1-[2-(trifluoromethyl)phenyl]sulfonyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.09 Å R-free 0.242 |
| 9GX0 Human PPAR-gamma ligand binding domain in complex with AKGO79 Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQG 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(4-methylphenyl)methoxy]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.10 Å R-free 0.260 |
| 9GX1 Human PPAR-gamma ligand binding domain in complex with AKGO80 Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQI 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(4-methoxyphenyl)methoxy]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.10 Å R-free 0.253 |
| 9GX2 Human PPAR-gamma ligand binding domain in complex with AKGO82 Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–503（269 aa）
Chain B
235–503（269 aa）
|
Not recorded | A1IP5 3-[(3-carboxyphenyl)methoxy]-4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.35 Å R-free 0.246 |
| 9GX3 Human PPAR-gamma ligand binding domain in complex with AKGO12 Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQE 4-[1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonylindazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 1.90 Å R-free 0.254 |
| 9GX4 Human PPAR-gamma ligand binding domain in complex with AKGO156 Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQC 4-[4-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.20 Å R-free 0.270 |
| 9GX5 Human PPAR-gamma ligand binding domain in complex with AKGO173 Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQJ 4-[5-chloranyl-1-[[2-chloranyl-6-(trifluoromethyl)phenyl]methyl]indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.45 Å R-free 0.270 |
| 9GX6 Human PPAR-gamma ligand binding domain in complex with AKGO166 Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQL 4-[5-chloranyl-1-(2,6-dimethylphenyl)carbonyl-indazol-3-yl]-3-phenylmethoxy-benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate pH 6.4-7.4
|
Resolution 2.10 Å R-free 0.251 |
| 9GX7 Human PPAR-gamma ligand binding domain in complex with WG17 Deposited 2024-09-27 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQH 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.20 Å R-free 0.271 |
| 9GXD Human PPAR-gamma ligand binding domain in complex with AKGO27 Deposited 2024-09-30 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQF 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-(2-phenylethoxy)benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.20 Å R-free 0.261 |
| 9GZ7 Human PPAR-gamma ligand binding domain in complex with AKGO29 Deposited 2024-10-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQ8 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(4-chlorophenyl)methoxy]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 1.80 Å R-free 0.247 |
| 9GZ8 Human PPAR-gamma ligand binding domain in complex with AKGO46 Deposited 2024-10-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQ7 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(1~{R})-1-phenylethoxy]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.20 Å R-free 0.254 |
| 9GZ9 Human PPAR-gamma ligand binding domain in complex with AKGO48 Deposited 2024-10-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQ6 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(3,4-dichlorophenyl)methoxy]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.10 Å R-free 0.261 |
| 9GZA Human PPAR-gamma ligand binding domain in complex with AKGO50 Deposited 2024-10-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQ5 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-(cyclohexylmethoxy)benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 1.90 Å R-free 0.238 |
| 9GZB Human PPAR-gamma ligand binding domain in complex with AKGO52 Deposited 2024-10-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQ4 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(3,5-dimethoxyphenyl)methoxy]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.20 Å R-free 0.274 |
| 9GZC Human PPAR-gamma ligand binding domain in complex with AKGO142 Deposited 2024-10-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQ3 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(3-methoxyphenyl)methoxy]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.30 Å R-free 0.255 |
| 9GZE Human PPAR-gamma ligand binding domain in complex with AKGO72 Deposited 2024-10-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–504（270 aa）
Chain B
235–504（270 aa）
|
Not recorded | A1IRD 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-(pyrimidin-2-ylmethoxy)benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.20 Å R-free 0.256 |
| 9GZF Human PPAR-gamma ligand binding domain in complex with AKGO88 Deposited 2024-10-03 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IQ2 4-[5-chloranyl-1-(phenylsulfonyl)indazol-3-yl]-3-phenylmethoxy-benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.65 Å R-free 0.258 |
| 9GZI Human PPAR-gamma ligand binding domain in complex with LW98 Deposited 2024-10-04 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1IRA 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(4-methylsulfonylphenyl)methoxy]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.70 Å R-free 0.264 |
| 9HX2 X-ray crystal structure of PPAR gamma Ligand Binding Domain in complex with CZ58 Deposited 2025-01-06 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
223–504（282 aa）
Chain B
223–504（282 aa）
|
Not recorded | A1IYE 2-[3-[(2~{R})-3-(4-bromophenyl)-4-oxidanyl-5-oxidanylidene-2~{H}-furan-2-yl]phenoxy]ethanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293.15 K；0.8 M SODIUM CITRATE, 0.15 M TRIS, pH 8.0
|
Resolution 2.85 Å R-free 0.282 |
| 9L3T PPARgamma Ligand binding domain in complex with piperine Deposited 2024-12-19 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
204–477（274 aa）
Chain B
204–477（274 aa）
|
Not recorded | AYR (2E,4E)-5-(2H-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)penta-2,4-dien-1-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；298 K；0.1 M Tris-HCl, 0.7 M sodium citrate
|
Resolution 2.36 Å R-free 0.255 |
| 9MAH PPARG-Spermine analogs Deposited 2025-03-14 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
234–505（272 aa）
Chain B
234–505（272 aa）
|
Not recorded | A1ENO N'-methyl-N'-phenyl-propane-1,3-diamine × 2 IMD IMIDAZOLE × 1 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.0 M Na3citrate, 0.1 M Imidazole pH 8.0
|
Resolution 2.10 Å R-free 0.234 |
| 9MAH PPARG-Spermine analogs Deposited 2025-03-14 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer；Protein × 4 PDB declaration: tetrameric |
Chain A
234–505（272 aa）
Chain B
234–505（272 aa）
|
Not recorded | A1ENO N'-methyl-N'-phenyl-propane-1,3-diamine × 4 IMD IMIDAZOLE × 2 GOL GLYCEROL × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；1.0 M Na3citrate, 0.1 M Imidazole pH 8.0
|
Resolution 2.10 Å R-free 0.234 |
| 9O9N Crystal structure of PPARgamma ligand binding domain (LBD) in complex with NCoR1 corepressor peptide and inverse agonist FX-909 Deposited 2025-04-18 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Not recorded | A1CAA (3P)-3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)-4-(methanesulfonyl)benzonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；0.1 M MES (pH 6.5), 0.2 M Ammonium Sulfate, 30% PEG 8000
|
Resolution 2.10 Å R-free 0.297 |
| 9OLC Crystal structure of PPARg ligand-binding domain in complex with NCoR1 peptide and FTX-6746 Deposited 2025-05-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | A1CCT (3P)-4-chloro-3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)benzonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.1 M MES pH 6.5, 0.1M Ammonium Sulfate, 24% PEG8000
|
Resolution 2.83 Å R-free 0.298 |
| 9OLC Crystal structure of PPARg ligand-binding domain in complex with NCoR1 peptide and FTX-6746 Deposited 2025-05-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
231–505（275 aa）
|
Not recorded | A1CCT (3P)-4-chloro-3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)benzonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.1 M MES pH 6.5, 0.1M Ammonium Sulfate, 24% PEG8000
|
Resolution 2.83 Å R-free 0.298 |
| 9OLC Crystal structure of PPARg ligand-binding domain in complex with NCoR1 peptide and FTX-6746 Deposited 2025-05-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
231–505（275 aa）
|
Not recorded | A1CCT (3P)-4-chloro-3-(5,7-difluoro-4-oxo-1,4-dihydroquinolin-2-yl)benzonitrile × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.1 M MES pH 6.5, 0.1M Ammonium Sulfate, 24% PEG8000
|
Resolution 2.83 Å R-free 0.298 |
| 9OLC Crystal structure of PPARg ligand-binding domain in complex with NCoR1 peptide and FTX-6746 Deposited 2025-05-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain D
231–505（275 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；291 K；0.1 M MES pH 6.5, 0.1M Ammonium Sulfate, 24% PEG8000
|
Resolution 2.83 Å R-free 0.298 |
| 9QFZ Human PPAR-gamma ligand binding domain in complex with LW132 Deposited 2025-03-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1I6M 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[(phenylmethyl)amino]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.10 Å R-free 0.265 |
| 9QG0 Human PPAR-gamma ligand binding domain in complex with LW128 Deposited 2025-03-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1I6U 5-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-6-phenylmethoxy-pyridine-2-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.10 Å R-free 0.250 |
| 9QG2 Human PPAR-gamma ligand binding domain in complex with LW86 Deposited 2025-03-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1I6S 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-(cyclopentylmethoxy)benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.00 Å R-free 0.242 |
| 9QG3 Human PPAR-gamma ligand binding domain in complex with LW129 Deposited 2025-03-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1I6T 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-2-fluoranyl-3-phenylmethoxy-benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.30 Å R-free 0.255 |
| 9QG4 Human PPAR-gamma ligand binding domain in complex with LW130 Deposited 2025-03-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1I6O 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[[3-(ethylcarbamoyl)phenyl]methoxy]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 1.90 Å R-free 0.234 |
| 9QG5 Human PPAR-gamma ligand binding domain in complex with LW112 Deposited 2025-03-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1I6P 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[[(3~{S})-piperidin-3-yl]methoxy]benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.30 Å R-free 0.244 |
| 9QG6 Human PPAR-gamma ligand binding domain in complex with LW109 Deposited 2025-03-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1I6N 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[[(3~{R})-piperidin-3-yl]methoxy]benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.70 Å R-free 0.270 |
| 9QGJ Human PPAR-gamma ligand binding domain in complex with LW90 Deposited 2025-03-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
235–505（271 aa）
Chain B
235–505（271 aa）
|
Not recorded | A1I6R 4-[5-chloranyl-1-[2-chloranyl-6-(trifluoromethyl)phenyl]carbonyl-indazol-3-yl]-3-[[(3~{S})-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-3-yl]methoxy]benzoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.9M-1.2M sodium citrate tribasic dihydrate, 0.1M sodium cacodylate
|
Resolution 2.20 Å R-free 0.255 |
| 9R6I Crystal structure of PPARgamma in complex with the bisphenol derivative BPS4BE Deposited 2025-05-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | A1JDE 4-(4-phenylmethoxyphenyl)sulfonylphenol × 1 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；1.2 M trisodium citrate, 100 mM HEPES, pH 7.5, 4.2% 1,2 propanediol
|
Resolution 1.70 Å R-free 0.229 |
| 9R6K Crystal structure of PPARgamma in complex with the bisphenol derivative BPPH Deposited 2025-05-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
231–505（275 aa）
|
Not recorded | A1JDD 4-[2-(4-oxidanyl-3-phenyl-phenyl)propan-2-yl]-2-phenyl-phenol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；0.8 M trisodium citrate, 100 mM HEPES, pH 7.5, 4.4% 1,2 propanediol
|
Resolution 2.30 Å R-free 0.259 |
| 9V8D PPARgamma ligand-binding domain in complex with PG08 Deposited 2025-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | PEG DI(HYDROXYETHYL)ETHER × 1 PGE TRIETHYLENE GLYCOL × 1 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；283 K；0.1 M KCl, 0.1 M MgCl2, 18% PEG Smear Medium, and 10% ethylene glycol
|
Resolution 1.44 Å R-free 0.201 |
| 9V8E PPARgamma ligand-binding domain in complex with PG11 Deposited 2025-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.1 M phosphate/citrate buffer (pH 5.5) and 30% PEG Smear Low
|
Resolution 1.70 Å R-free 0.215 |
| 9V8F PPARgamma ligand-binding domain in complex with PG14 Deposited 2025-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
233–505（273 aa）
|
Not recorded | PEG DI(HYDROXYETHYL)ETHER × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.1 M Bis-Tris HCl (pH 6.2 to 6.5), 23% PEG 3,350, and 0.2 M MgCl2
|
Resolution 1.75 Å R-free 0.230 |
| 9V8G PPARgamma ligand-binding domain in complex with PG08-NL Deposited 2025-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.2 M sodium malonate (pH 7.0) and 20% PEG 3,350
|
Resolution 1.39 Å R-free 0.182 |
| 9V8H PPARgamma ligand-binding domain in complex with PG08-NL and rosiglitazone Deposited 2025-05-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
231–505（275 aa）
|
Not recorded | BRL 2,4-THIAZOLIDIINEDIONE, 5-[[4-[2-(METHYL-2-PYRIDINYLAMINO)ETHOXY]PHENYL]METHYL]-(9CL) × 1 PGE TRIETHYLENE GLYCOL × 1 PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；0.2 M sodium malonate (pH 7.5 to 8.0) and 15 to 20% PEG 3,350
|
Resolution 1.39 Å R-free 0.190 |
369 other PDB entries and 500 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | PPARG_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A； PDBConstruct 5–286； UniProt 223–504 Author chain B； PDBConstruct 5–286； UniProt 223–504 |
